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"Forty-two!" yelled Loonquawl. "Is that all you've got to show for seven and a half million 
years' work?"  
"I checked it very thoroughly," said the computer, "and that quite definitely is the answer. I 
think the problem, to be quite honest with you, is that you've never actually known what the 
question is." 
Douglas Adams,  
The Hitchhiker's Guide to the Galaxy, 1979 
 
 
Any model that fits the data acceptably well will be only one of many possible data- 
generating mechanisms that we cannot rule out given our limited data and understanding.  
Sander Greenland,  
Am J Epidemiol. 2017 Sep 15;186(6):639-45 
  
  
  
ABSTRACT 
Introduction  
Reperfusion therapy by intravenous thrombolysis (IVT) and/or endovascular thrombectomy 
(EVT) are established treatments in ischaemic stroke. Cerebral oedema (COED), caused by 
dysfunction the blood brain barrier (BBB), is common early after acute ischaemic stroke 
(AIS), can aggravate the symptoms and worsen the prognosis. Data on predictors and the 
effect of recanalization on early COED is limited. A large infarction with COED involving 
the middle cerebral artery (MCA) can be life-threatening. Decompressive hemicraniectomy 
(DHC) reduces mortality and may have a positive effect on functional outcome in younger 
patients. Animal data suggest that imatinib, a tyrosine kinase inhibitor, may restore BBB 
integrity, thereby reducing haemorrhagic transformation (HT) and COED. The aim of this 
doctoral thesis was to contribute to the understanding of clinical aspects of COED in patients 
with AIS of the anterior circulation.  
Methods 
Paper I, II and IV reported retrospective, observational studies using data from the Safe 
Implementations of Treatments in Stroke (SITS) International Stroke Registry, a prospective, 
multinational registry. These studies included patient data recorded using the SITS Registry 
data collection protocols for IVT and EVT, and to some extent general stroke, in time periods 
between 2002 and 2019. All patients had presumed ischaemic stroke. Paper III reported a 
phase 2, randomized, open-label, pilot study of imatinib in patients who received IVT after 
ischaemic stroke at 5 hospitals in Stockholm 2011-2014. All papers evaluated COED using 
the SITS COED scale (no, mild, moderate or severe COED). Outcomes at 3 months were 
functional outcome using the modified Rankin scale (mRS) score and death of any cause. 
Results 
In paper I, the most important predictors of COED after AIS were assessed. Among 42 187 
patients (median age 70 years), 12.5% had mild COED on follow-up imaging (22-36 hours or 
any extra investigation) and 10.2% had moderate or severe COED. Baseline National 
Institutes of Health Stroke Scale (NIHSS) score, followed by hyperdense artery sign (HAS), 
were the strongest predictors for COED. Additionally, higher blood glucose, impaired level 
of consciousness and imaging signs of early infarction at baseline were predictors for COED. 
Increasing degree of COED at 22-36 hours was associated with increasing mortality and 
worse functional outcome at 3 months. 
In paper II, the effect of recanalization on COED was assessed. Reperfusion therapy was 
administered to the 22 184 patients (median age 71 years and NIHSS score 16): only IVT 
(82.6%), IVT and EVT (13.8%) or only EVT (3.6%). Overall, recanalization was associated 
with a 10.6% (p<0.001) absolute risk reduction of moderate to severe COED at 22-36 hours, 
relative risk (RR) 0.55 (95% CI 0.52-0.58). Two models with high predictive ability provided 
the following estimates: adjusted OR 0.52 (95% CI, 0.46-0.59) and, with additional 
adjustment for parenchymal haemorrhage (PH), OR 0.46 (95% CI, 0.41-0.52). Moreover, 
recanalization was associated with a 13.6% (p<0.001) absolute reduction of mortality at 3 
months, RR 0.58 (95% CI 0.55-0.61), adjusted OR 0.48 (95% CI 0.45-0.53). 
In paper III, 60 patients were randomized (15 patients in low-dose, 14 patients in medium 
and high-dose and 17 patients in control). Four serious adverse events (2 in control and 2 in 
low-dose group) resulted in the death of 3 patients. Of the dead patients 2 were allocated to 
low-dose group but of these, 1 did not receive imatinib and 1 patient had received only 2 
doses. In the per protocol analysis, there were 21 haemorrhagic infarctions (6 in control), 3 
PH (1 in control) and 4 remote parenchymal haemorrhages (0 in control). There were 33 
cases of COED with moderate to severe COED being less frequent with higher doses, and no 
cases of moderate to severe COED in the high-dose group. After adjustment for EVT, the 
mean improvement in the NIHSS score compared to controls was 2 points (p=0.259) for the 
low-dose group, 3 points (p=0.106) for the medium-dose groups and 5 points (p=0.012) for 
the high-dose group. Functional independence (mRS 0-2) at 3 months was observed in 61% 
of the control group and 72% of all imatinib-treated patients; OR, adjusted for EVT, was 2.33 
(95% CI 0.48-11.44). 
Paper IV reported anterior circulation AIS patients that underwent DHC. In 684 patients 
from 35 countries median age was 56 years and NIHSS score at baseline 18 and 98.1% 
received reperfusion therapy. Moderate to severe COED was detected in in 76.0% and PH in 
25.8% at 22-36 hours follow-up imaging scans. Surgery-related details, for example timing of 
DHC, were not registered. Mortality at 3 months was 32.7% (159/486). Among baseline 
variables, only increasing age was independently associated with death (OR 1.06, 95% CI 
1.03-1.08). Good outcome (mRS 0-3) at 3 months was observed in 13.9% (66/475) and mRS 
0-4 was observed in 39.4% (187/475). Outcomes differed between patients aged ≤60 years 
≥61 years (25.2% versus 47.8% for mortality and 16.6% versus 8.4% for good outcome). 
Right-sided involvement of vascular territory was more common than left-sided. 
Conclusions 
The most important baseline predictors for early COED are NIHSS score, HAS, higher blood 
glucose, decreased level of consciousness, and signs of acute infarction at baseline. This 
finding can be used to improve selection and monitoring of patients for drug or surgical 
treatment. 
In patients with AIS, recanalization was associated with a lower risk for early COED even 
after adjustment for higher rate of PH in recanalized patients. 
Imatinib is safe and tolerable and may reduce neurological disability in patients treated with 
IVT after AIS. A confirmatory randomized trial is ongoing.  
DHC in routine clinical practice may have worse outcomes than randomized trials, although 
there are caveats due to short follow-up of the patients in this study. Right-sided arterial 
  
occlusions were more common than left-sided, which indicates a tendency to perform DHC 
in infarctions of the right hemisphere. 
In general, this doctoral thesis added new knowledge about several aspects of COED in AIS 
and a potential new pharmacological therapy for acute ischaemic stroke. Further research is 
required to confirm these results which are based on 3 retrospective observational studies and 
one phase 2 pilot study. In fact, an efficacy trial of imatinib is now ongoing.  
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  1 
1 INTRODUCTION 
1.1 OVERVIEW OF STROKE 
The first definition of stroke may have originated from Hippocrates of Kos (460-370 BC), 
who used the Greek word for apoplexy, "being struck down", to describe a sudden loss of 
consciousness due to brain disease [1]. Using the explications of humoral theory, the cause of 
this brain disease was believed to be an accumulation of black bile in the arteries of the brain. 
The word "stroke" has been used in medicine since 1689 [2]. In modern medicine, stroke has 
until recently been a strictly clinical definition based on an acute loss of focal neurological 
function of vascular cause, in the brain, retina or spinal cord, and lasting more than 24 hours 
[3, 4].  
The two main pathological subtypes of stroke are ischaemic stroke and haemorrhagic stroke, 
where the latter term usually includes both intracerebral haemorrhage and subarachnoid 
haemorrhage. The proportions of these vary with age, race and ethnic origin [4]. Of all 
patients with stroke (excluding subarachnoid haemorrhage) registered in the Swedish Stroke 
Registry 2018, 86% had ischaemic stroke (mean age 75 years) and 13% had intracerebral 
haemorrhage (mean age 74 years) [5].  
Every year, 13.7 million people are affected by stroke, ischaemic or haemorrhagic. With 5.5 
million people dying of stroke annually, this is the second most common cause of death in the 
world [6, 7]. It is the number one cause of neurological disability in adults, worldwide and in 
Sweden [8].  
Although the traditional definition of stroke was prevailing throughout most of the time 
period that the studies reported in this doctoral thesis were carried out, there has been a 
change in recent years. During the last decade or so, the definition of stroke has been 
gradually updated because of advances in neuroimaging using magnetic resonance imaging 
(MRI) which allows the detection of ischaemic brain injury with high precision. In 2013 an 
updated terminology was published, from the American Heart Association, in which both 
clinical and tissue criteria were incorporated [2]. This tissue-based definition of stroke allows 
for episodes of neurological dysfunction to be included if neuroimaging or autopsy shows 
evidence of focal ischaemic or haemorrhagic injury that explains the symptoms, and other 
aetiologies are excluded. In the absence of pathological or imaging evidence of tissue 
damage, however, a necessary criterion for the diagnosis of stroke is that the symptoms last 
24 hours or more. Similar definitions of stroke are being implemented in the World Health 
Organization's 11th version of International Classification of Diseases [9, 10]. For example, 
the description of "cerebral ischaemic stroke" (8B11) states that "evidence of acute infarction 
may come either from symptom duration lasting more than 24 hours, or neuroimaging or 
other technique in the clinically relevant area of the brain." This description excludes the 
retina.  
 2 
1.2 ISCHAEMIC STROKE 
The incidence of ischaemic stroke by country is shown in figure 1. Both globally and in 
Sweden, the incidence of ischemic stroke is decreasing, probably because of improved 
primary and secondary prevention [5-7]. The prevalence, however, is increasing slightly, 
probably because of reduced stroke mortality, better secondary prevention and better 
detection [6]. Annually, 2.7 million people die of ischaemic stroke [7]. 
 
Figure 1. The global distribution of ischaemic stroke incidence by country. Data from the 
Global Burden of Disease Study 2017. From Campbell et al. [6]. Reproduced with 
permission from Springer Nature Customer Service Centre GmbH. Copyright 2019 Springer 
Nature. 
 
Figure 2 illustrates the three basic mechanisms for acute ischaemic stroke (AIS): large-artery 
stenosis (atherothrombotic), cardioembolic and small vessel disease which can cause lacunar 
infarction but also can manifest as leukoaraiosis or haemorrhagic events.  
These basic mechanisms are utilized for aetiological classification in the Trial of ORG 10172 
in acute stroke treatment (TOAST) criteria which have been widely used [11, 12]. The 
TOAST classification scheme for ischaemic stroke contains the following subtypes: large-
artery atherosclerosis, cardio-embolism, small vessel occlusion and other determined 
aetiologies. In addition, the TOAST criteria allow for a patient being classified as having 
undetermined cause of stroke. The ASCOD classification, proposed in 2009 with an update in 
2013, suggested a characterization of every patient according to one of five of the following 
so-called phenotypes: A for atherosclerosis, S for small vessel disease, C for cardiac source, 
O for other cause, D for dissection [13]. Regardless of classification system, the relative 
proportions of different categories vary depending on age, geographical location, race and 
ethnic origin. In North American and European studies, approximate proportions are: 25% 
can form when the lipid core of atherosclerotic plaques 
is exposed to the bloodstream, which can be caused 
by inflammation and ulceration of the fibrous cap of 
plaques. These thrombi can occlude the atherosclerotic 
vessel or, more commonly in the large vessels relevant to 
stroke, can embolize distally.
In western populations, the most frequent location of 
atherosclerotic plaques that can cause ischaemic stroke 
is the internal carotid artery, just after its bifurcation 
from the common carotid artery. This is hypothesized 
to relate to reduced shear stress on the arterial wall 
at that site. Low shear stress is associated with intimal 
thickening and reduced nitric oxide release that are 
thought to mediate this susceptibility to cholesterol 
plaque development25. Although intracranial athero-
sclerosis is sometimes observed in patients in western 
countries, usually in heavy smokers and individuals with 
diabetes mellitus26, it is much more common in Asia27. 
Indeed, intracranial atherosclerosis is reported to cause 
~30–50% of ischaemic strokes in Asian patients com-
pared with 5–10% of strokes in white patients28. This 
disorder presents a challenge for standard thrombec-
tomy, as it is associated with higher reocclusion rates 
after thrombectomy and has an increased requirement 
for stenting, the latter carrying a greater risk of com-
plications, particularly bleeding related to the use of 
antiplatelet medications to maintain stent patency29.
Small vessel disease. As the name suggests, small vessel 
disease affects the smaller arteries and arterioles of the 
brain. Small vessel disease can manifest in several ways, 
including lacunar stroke, leukoaraiosis (white matter 
changes that can be observed as T2-hyperintensities 
on MRI or hypodensities on CT), cerebral microbleeds 
and intracerebral haemorrhage. Deep subcortical and 
brainstem structures are supplied by small-calibre per-
forating arteries that arise from much larger arteries of 
the circle of Willis, exposing the small vessels to high 
pressure that could predispose to lipohyalinosis (nar-
rowing of the small cerebral vessels). Lipohyalinosis is 
not the only cause of small subcortical infarcts, and tra-
ditional clinical patterns defined as lacunar syndromes 
have limited specificity for small vessel disease-related 
stroke. Atherosclerosis of the parent artery with occlu-
sion of the perforating vessel origin is another important 
mechanism of lacunar clinical syndromes30. In rare cases, 
monogenic disorders can cause small vessel disease, 
for example, CADASIL, which typically presents with 
migraine followed by lacunar infarcts and then dementia.
Arterial dissection. A dissection or tear in the inti-
mal layer of an artery with intramural thrombus is 
an important cause of stroke, particularly in younger 
patients. Most dissections that cause ischaemic stroke 
are in the extracranial c rotid and vert bral arteries and 
can occlude the artery at the site of dissection or cause 
thrombus formation and distal embolism. Although 
vary ing degrees of cervical trauma can cause dissection, 
it is often quite minor; for some individuals, forceful 
coughing or sneezing may be sufficient to cause dissec-
tion. Furthermore, dissections are often spontaneous. 
Some collagen and connective tissue diseases can predis-
pose to arterial dissections, although, aside from fibro-
muscular dysplasia and Ehlers–Danlos syndrome, these 
disorders are rarely identifiable with currently available 
tests and limited genetic contributions to dissection risk 
have been discovered to date31. As a result, testing for 
an underlying connective tissue disorder is not routine.
Cerebral vasculitis. Vasculitis of the cerebral arteries is 
rare but can occur as a primary central nervous system 
(CNS) angiitis or as a manifestation of a systemic vas-
culitis. In these conditions, vessel wall inflammation 
can lead to luminal narrowing and thromboembolism 
causing ischaemic stroke (and sometimes intracerebral 
haemorrhage).
Incidence (per 
100,000 population)
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large artery stenosis (atherosclerosis), 20% cardiogenic embolism, 25% small vessel disease, 
5% unusual causes (for example arterial dissection or arteritis) and 25% of unknown cause 
(so-called cryptogenic) [14]. Among the group of patients with unknown cause, a proportion 
of patients have embolic source as a likely mechanism on the basis of clinical evaluation, so-
called embolic stroke of undetermined source [14]. The proportion of patients where the 
cause of stroke is unknown according to traditional criteria, but an embolic source is 
suspected, varies among studies but may average at approximately 17% of all ischaemic 
stroke patients [15]. 
 
 
Figure 2. Ischaemic stroke mechanisms and the concepts of ischaemic penumbra and core. 
Illustrated stroke mechanisms are cardioembolic in atrial fibrillation, large-artery stenosis 
with artery-to-artery embolism from an atherosclerotic carotid artery and lacunar infarction 
in small vessel disease due to lipohyalinosis or parent artery atherosclerosis. Here, a 
thrombus (clot) is occluding the middle cerebral artery (MCA). As a compensation, the 
territory of the MCA receives retrograde flow via collateral circulation through 
leptomeningeal anastomoses with the anterior cerebral artery (ACA) or posterior cerebral 
artery (PCA). The ischaemic penumbra is the region where blood flow is reduced below the 
threshold for electrical activity, causing a neurological deficit, but still sufficient for the 
tissue to survive. The ischaemic core consists of regions without sufficient collateral blood 
flow that become irreversibly injured (infarcted). The core expands over time at the expense 
of the penumbra. If reperfusion occurs quickly, the core remains small and the contribution 
of the penumbra to the neurological deficit may be reversed. From Campbell et al. [6]. 
Reproduced with permission from Springer Nature Customer Service Centre GmbH. 
Copyright 2019 Springer Nature. 
Reversible cerebral vasoconstriction syndrome. Reversible 
cerebral vasoconstriction syndrome presents with recur-
rent thunderclap (abrupt onset) headaches and can cause 
ischaemic stroke, intracerebral haemorrhage or focal 
subarachnoid haemorrhage through vasospasm and vas-
cular dysregulation. The precise aetiology is unknown 
and vasospasm might not be presen  on the initial arterial 
imaging32. This is a separate entity to the vasospasm that 
occurs after aneurysmal subarachnoid haemorrhage 
that can also cause ischaemic stroke.
Cardiac causes of stroke
Atrial fibrillation. Atrial fibrillation and flutter allow 
blood to stagnate, particularly in the left atrial append-
age, which can allow thrombosis and subsequent 
embolism to the cerebral or systemic circulation. Both 
permanent and paroxysmal atrial fibrillation increase 
the risk of cardioembolic ischaemic stroke33.
The prevalence of atrial fibrillation is increasing 
with an ageing and increasingly obese population34. 
Other risk factors for atrial fibrillation include chronic 
hypertension, ischaemic heart disease, valvular disease, 
diabetes mellitus, hyperthyroidism, excessive alcohol 
consumption and obstructive sleep apnoea35. The risk of 
ischaemic stroke in patients with atrial fibrillation can be 
estimated using the CHA2DS2-VASc score, which takes 
into account age, history of stroke, sex, diabetes mellitus, 
hypertension, heart failure and vascular disease, and can 
be used to indicate patients who should be considered 
for prophylactic anticoagulation36.
Patent foramen ovale. In utero, the cardiac foramen 
ovale allows the flow of placental oxygenated blood from 
the right to the left atrium. After birth, the increase in 
pressure in the left side of the heart closes the flap 
in most people but ~25% of individuals have a degree 
of residual patency (that is, a PFO)37. This patency cre-
ates a potential mechanism for paradoxical embolism, 
which could lead to ischaemic stroke. The importance 
of PFO in young adult stroke has been highlighted by 
the significant reduction in risk of recurrent ischaemic 
stroke after endovascular closure of PFO38–40. Various 
risk factors have been proposed to indicate a higher risk 
of stroke in individuals with PFO, including the extent of 
shunting and an aneurysmal (that is, hypermobile) 
interatrial septum.
Infective endocarditis. Bacterial endocarditis can cause 
septic emboli in the brain, leading to ischaemic stroke. 
In addition to the increased risk of stroke, bacterial 
endocarditis presents difficulties for stroke treatment as 
it is associated with an increased risk of haemorrhagic 
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Figure 3. Cellular mechanisms in cerebral ischaemia. This schematic model illustrates that 
the sudden occlusion of a cerebral artery initiates many processes that eventually lead to cell 
death. Reduced blood flow causes lack of oxygen and glucose (energy mismatch) in neurons, 
glia and endothelial cells while also causing blood-brain barrier (BBB) dysfunction. The 
electrical activity of neurons is impaired by of lack of ATP, necessary to uphold the 
transmembrane gradient. Anoxic depolarization of neurons leads to neurotransmitter release 
while active clearance of excitatory amino acids is decreased due to lack of energy. This 
results in increased extracellular levels of glutamate and, through ion channels, increased 
intracellular calcium in neurons and glia. The excess intracellular calcium triggers 
mechanisms that initiate pathways to cell death. In addition, BBB dysfunction and release of 
cytokines and other signalling molecules from astrocytes, microglia and oligodendrocytes 
leads to an inflammatory response that triggers pathways to cell death. From Campbell et al. 
[6]. Reproduced with permission from Springer Nature Customer Service Centre GmbH. 
Copyright 2019 Springer Nature. 
 
 
 
 
of oxygen and glucose to the brain). When this sup-
ply is interrupted, as in stroke, neurons can no longer 
maintain their transmembrane gradient, leading to the 
impairment of neuronal signalling. In addition, anoxic 
depolarization (that is, sudden, progressive neuro-
nal depolarization during states of inadequate blood 
supply to the brain) at presynaptic terminals leads to 
neurotransmitter release51. The clearing of excitatory 
neurotransmitters from the synaptic cleft is an active, 
energy-dependent process; thus, neurotransmitter 
concentrations (including glutamate) increase during 
ischaemic stroke.
Particular properties of the N-methyl-d-aspartate 
(NMDA) receptor cause additional problems. At typi-
cal resting membrane potentials, conductance through 
the open NMDA receptor is limited as the channel 
is blocked by extracellular magnesium. However, 
upon depolarization, the magnesium is removed and 
conduction is substantially higher52, leading to cal-
cium influx and the secondary release of large amounts 
of calcium from intracellular stores53,54. The resulting 
increased intracellular calcium concentration leads to 
the activation of several calcium-dependent processes 
such as the activation of neuronal nitric oxide synthase 
with consequent free radical production55, and the initi-
ation of cell death processes including apoptosis, necro-
sis, necroptosis and autophagy. Deg neration of distant 
nerve fibres (that is, Wallerian degeneration) in tracts 
that serve the infarcted brain (such as the corticospinal 
tract for motor weakness) occurs in animal models56 
and can be detected using diffusion tensor imaging in 
humans, in whom changes in early fractional anisotropy 
predict long-term clinical outcome57. These systems are 
well defined in rodent models of stroke, and interfering 
with NMDA signalling58, neuronal nitric oxide synthase 
activity59 and p53 activation following DNA damage60 
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The occlusion of an artery in AIS causes an impaired perfusion in the affected brain region. 
When the blood flow is reduced below a certain threshold, the neurons in that region become 
electrically inactive, precipitating a clinical deficit. Please see figure 3 for a short description 
of cellular mechanisms in cerebral ischaemia. 
Figure 4 shows some thresholds of the cerebral blood flow (CBF) required to maintain brain 
tissue structure and function. In animal studies, monkeys gradually developed a neurological 
deficit as CBF in a region of the brain was lowered, from mild paresis at 22 ml/100 g/min to 
complete paralysis at 8 ml/ 100 g/min [16]. The lower the remaining flow, the shorter is the 
time until neurons are irreversibly injured. A sharp decline of CBF, to less than 12 ml/100 
g/min or thereabout, will cause cell death and infarction more quickly [16]. If blood flow is 
reduced to between 16 and 18 ml/100 g/min, the electrical activity of neurons ceases but the 
tissue may survive for longer [17, 18]. Meanwhile, if the duration of ischaemia is protracted, 
the tissue may become infarcted. 
 
Figure 4. In an ischaemic region of the brain, the survival of tissue is a function of the degree 
of impairment of cerebral blood flow (CBF), and the duration of ischaemia. This figure 
shows some thresholds of CBF required to preserve of brain tissue. Dashed lines indicate the 
reaction of neurons to decreased blood flow, as seen in animal experiments. The grey area 
represents structural damage (infarction). With time, the ability to sustain ischaemia 
decreases so that the infarction grows in size. From: Heiss [16], slightly modified. 
Reproduced with permission. Copyright 2011 Karger Publishers, Basel, Switzerland. 
 
The ischaemic penumbra is a region where cerebral perfusion is decreased because of an 
occluded artery, but not low enough to cause infarction at once. The infarction core, or umbra 
(Latin for shade), is brain tissue that has already infarcted. If the occlusion remains, the 
 Heiss
 
Cerebrovasc Dis 2011;32:307–320310
 Many interrelated biochemical mechanisms are in-
volved in or contribute to ischemic cell damage, and 
therefore various markers can be used as indicators of 
ischemic thresholds and of reversible or irreversible func-
tional deficits [reviews in  16, 17 ]. In accordance with the 
critical role that the supply of energy-rich substrates plays 
in brain function, cerebral ATP content and cerebral 
metabolic rate of glucose exhibit a threshold dependency 
similar to the electrophysiological variables. Actually, the 
mean thresholds for ATP depletion (18.5 ml/100 g/min) 
and spontaneous neuronal activity (18 ml/100 g/min) are 
identical. However, it should be noted that the decrease 
in ATP content sets in at a slightly higher flow value, at 
which point glucose consumption is increased in an at-
tempt to compensate for the lack of oxygen. At that flow 
level, local hypoxia induces anaerobic glycolysis, result-
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volume of the core will increase while the penumbra decreases. The speed of this process 
varies between individuals depending on the capacity of the collateral circulation and other 
factors. Please see figure 2 for an of illustration of the concepts of ischaemic penumbra and 
ischaemic core, and their dependence on collateral flow in middle cerebral artery (MCA) 
occlusion. 
The site and size of the occluded artery is a determinant of the extent of ischaemia and is 
important for the clinical outcome in AIS [17]. In general, larger diameter correlates with 
larger volume of ischaemia and to cortical symptoms such as aphasia and neglect, thereby 
with more severe neurological impairment unless revascularization is achieved, either 
spontaneously or through reperfusion therapy [19, 20]. In small vessel disease, the occluded 
arteries are typically less than 0.5 mm in diameter. In large artery occlusion (LAO), on the 
other hand, usually one of the following arteries of diameter 1 between 1 to 4 mm is 
occluded: intracranial carotid artery (ICA), terminal ICA, the proximal (M1 branch) of the 
MCA, the secondary (M2) or tertiary (M3) branches of the MCA, the anterior cerebral artery 
(ACA), the basilar artery, and the posterior cerebral artery (PCA) [17]. In two American 
studies, LAO was the cause of AIS in 46.0% and 24.1% of patients that presented at medical 
centres or were being transported by emergency medical services [19, 21].  
Ischaemic core volume before reperfusion therapy is known to predict clinical outcome in 
patients with anterior circulation LAO. In a retrospective analysis of 185 patients presenting 
with anterior circulation LAO, it was observed that 25% of patients with anterior circulation 
LAO were so-called fast progressors, defined as an ischaemic core >70 ml within 6 hours of 
stroke onset while approximately 55% of patients were slow progressors with an ischaemic 
core ≤30 ml when presenting between 6 and 24 hours [22]. 
1.2.1 Acute treatment of ischaemic stroke  
Stroke unit care and reperfusion therapy by intravenous thrombolysis (IVT) within 4.5 hours 
of symptom onset, and/or endovascular thrombectomy (EVT), within 24 of symptom onset in 
anterior circulation AIS are the only evidence-based treatments for AIS and are 
recommended by national and international practice guidelines [6, 17]. 
In a stroke unit, multidisciplinary treatment together with monitoring and nursing care 
measures that prevent complications, improves functional outcomes and reduces stroke 
mortality [23, 24]. 
In order to achieve revascularization, which is a restoration of blood that rescues the 
penumbra, the arterial artery must become open and capillary blood flow restored. 
Restoration of patency of an occluded artery is recanalization while restoration of 
downstream capillary flow is reperfusion [25]. In this way, recanalization is necessary, but 
not sufficient, for reperfusion to occur [26]. In routine practice, measurements of reperfusion 
are often based on angiographic appearance of the vascular territory, as in the modified 
Treatment in cerebral ischaemia scale (mTICI) [27]. Other methods, for example computed 
tomography (CT) with perfusion sequences, have been used [28].  
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IVT with recombinant tissue plasminogen activator (tPA), alteplase, administrated within 4.5 
hours after first stroke symptoms, has been shown to improve the long-term functional 
outcome after stroke [29, 6]. Randomized trials evaluating tPA in ischaemic stroke were 
conducted in the 1990s and the drug was approved by the U.S. Food and Drug 
Administration in 1996. Tenecteplase, which is tPA that has been modified to have a longer 
half-life, is sometimes used off-license in AIS awaiting ongoing trials. Based on methods for 
selection of patients in the first trials that evaluated tPA, the diagnostic approach was for 
many years to use a strictly clinical definition of stroke and rely on neuroimaging to exclude 
either haemorrhage or a large infarction that would be a contraindication to treatment. With 
advanced neuroimaging the time window for treatment is now being extended beyond 4.5 
hours in selected patients. The WAKE-UP trial and the EXTEND trial used imaging-based 
criteria for treatment with tPA [30, 31]. They found that tPA treatment can improve 
functional outcome in patients with uncertain time of onset, such as wake-up stroke, and in 
patients up to 9 hours after time of last known well.  
The outcomes after treatment with both IVT and EVT are time dependent and the earlier the 
treatment is given the better the outcome. The more proximal the arterial occlusion is, the 
lower is the recanalization rate in IVT. For example, with transcranial doppler it was found 
that complete recanalization within 2 hours after tPA administration was achieved in 44% of 
patients with distal MCA occlusions, in 30 % of proximal MCA occlusions, in 27% of 
tandem ICA/MCA occlusions and in only 6% of terminal ICA occlusions [32]. EVT, on the 
other hand, has so far achieved better results in the larger, more proximal arteries.  
Since 5 randomized clinical trials, published in 2015, showed that EVT in selected patients 
with AIS due to LAO, improves functional outcome, EVT has become established therapy. 
EVT has higher rates of recanalization than IVT. Proportions of successful recanalization 
varies between studies, but are usually between 60% and 90% [33, 17]. In 2018, the DAWN 
and DEFUSE trials demonstrated that EVT up to 24 hours has an effect in selected patients 
which has also been incorporated in latest guidelines [34, 35]. 
1.3 BLOOD-BRAIN BARRIER DISRUPTION IN ISCHAEMIC STROKE 
The blood-brain-barrier (BBB) separates intravascular and interstitial spaces so that the 
central nervous system (CNS) is separate from the peripheral blood circulation [36-41]. The 
BBB functions as a selective barrier that restricts and controls exchanges between the blood 
and brain. It protects the CNS while it maintains homeostasis regarding for example water, 
ions, and hormones [41]. The BBB is created by endothelial cells, pericytes, and basement 
membranes. Some of the special features of brain endothelial cells that contribute to the 
tightness of BBB are the specialized tight junctions between cells, a lack of fenestrations and 
the continuous basement membranes. The cells that create the BBB are part of the 
neurovascular unit, please see figure 5. The neurovascular unit consists of several 
components that interact in order to maintain function and stability of the BBB [41]. Among 
these components are endothelial cells, pericytes, smooth muscle cells, neurones, and 
astrocytes [42, 39, 41]. 
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Figure 5. Cerebral arterioles and capillaries, the neurovascular unit and the blood-brain 
barrier (BBB). Pial arteries in the subarachnoid space branch into penetrating arteries 
surrounded by the Virchow-Robin spaces that contain brain interstitial fluid. Arterioles, 
covered by smooth muscle cells, are branched off from penetrating arteries. Most distal in the 
arterial tree are the capillaries where endothelial cells, connected by tight junctions and 
surrounded by pericytes, create the BBB. From Zhao et al. [39]. Reproduced with 
permission. Copyright 2015 Elsevier Inc.  
 
The forces driving fluid across the BBB are described by Starling´s equation, in which the 
movement of fluid is proportional to the sum of two main pressure gradients: the net osmotic 
pressure and the net hydrostatic pressure [36, 40]. The net osmotic pressure is affected by the 
number of particles that are dissolved in the blood and in the interstitial fluid. The net 
hydrostatic pressure is affected by precapillary resistance, capillary resistance, postcapillary 
resistance, interstitial volume and tissue compliance. The ability of these pressure gradients to 
cause flux over the BBB depends on the conductivity of the BBB, which can be described as 
being is divided into two coefficients, one for each pressure gradient: osmotic conductivity 
and hydraulic (hydrostatic) conductivity. 
1.3.1 Cerebral oedema and haemorrhagic transformation 
On the molecular level, cerebral ischaemia triggers processes that result in cell swelling and 
impairment of the BBB. Please see figure 6. Cytotoxic oedema, is caused by an inflow of 
water into the cells without BBB disruption and occurs within minutes of ischaemic injury. It 
is caused by failure of cell membrane pumps, which results in intracellular accumulation of 
  9 
sodium and calcium ions, and water, in brain cells, particularly astrocytes. This process can 
lead to cell oncotic death but is not in itself associated with increased brain volume or brain 
swelling [43, 36, 44-47, 40, 48].  
 
 
Figure 6. Development of oedema in 
cerebral ischaemia. In the normal state, 
intravascular Na+ concentrations are the 
same as those in extracellular space in the 
parenchyma, while intracellular Na+ 
concentrations in neurons are much lower. 
A. Cytotoxic oedema. Early during 
ischaemia, ATP-dependent active transport 
channels decrease their activity so that ions, 
mostly Na+, enter the cells followed by 
water. This causes the cells to swell and may 
cause so-called oncotic cell death. At this 
stage, the endothelial cells are not affected. 
B. Ionic oedema. The osmotic gradient that 
was created during cytotoxic oedema pulls 
electrolytes, mostly Na+, from the 
endothelium. The net effect is that Na+ 
travels from the intravascular compartment 
to the extracellular space. The blood-brain 
barrier (BBB) is still intact.  
C. Vasogenic oedema. Swollen cells rupture 
and endothelial tight junctions are split so 
that proteins, electrolyes and fluid exit from 
the vessel and accumulate in the 
parenchyma. The BBB is broken.  
From Liebeskind et al. [48]. Reproduced 
with permission. Copyright 2019 Wolters 
Kluwer Health Inc. 
 
There is a stepwise progress towards increasingly more severe transvascular oedema where 
fluid and proteins move across the BBB. This causes brain swelling because of an increased 
amount of water in the interstitial space [36, 45, 47, 40, 49, 48]. In its earlier stages, the 
process is driven by sodium and water gradients, a process known as ionic oedema [36, 45]. 
Later, the BBB is broken down which causes vasogenic oedema which causes the leakage of 
proteins and electrolytes into the interstitial space [36, 44].  
Liebeskind et al  Cerebral Edema and LHI  2621
hemisensory loss, dysphagia, aphasia, gaze deviation, neglect, 
hemianopia, and reduced consciousness.16,24,26,53,54 A constel-
lation of early symptoms, referred to as severe hemispheric 
syndrome—gaze deviation, language and visuospatial defi-
cits, hemiparesis—has been described.55 The development 
of severe cerebral edema distinguishes MCE following LHI 
with clinical signs that are suggestive of worsening initial LHI 
symptoms, headache and emesis,55 and new or further impair-
ment of consciousness.24
Predicting Infarc ion and Edem  Formation
Infarction
The most reliable imaging predictors of progression to LHI 
are considered early CT finding  of hypodensity in >50% of 
the MCA territory and a lesion volume >145 mL on DWI, 
assessed within 14 hours of onset.19,56 Attenuation of the lenti-
form nucleus, loss of the insular ribbon, or hemispheric sulcal 
effacement are significantly associated with subsequent MCA 
infarct location and extension.57 Further, the presence of 2 or 
3 of these signs is associated with extended MCA infarct and 
poor outcome.57 The combination of MCA and internal ca-
rotid artery infarction has previously been identified as an in-
dependent risk factor for LHI.25
Other factors predicting the development of LHI develop-
ment include involvement of additional vascular territories, a 
hyperdense MCA sign (with 71% sensitivity and 84% speci-
ficity), a perfusion deficit in >66% of the MCA territory on CT 
within 6 hours of stroke onset, and infarct core of >27.9% on a 
cereb al blood flow map.46,58
Cerebral Edema
Several neuroimaging, clinical, and serum biomarkers have 
been investigated as prognostic predictors of severe cerebral 
edema; however, their usefulness remains unclear.14 Predictors 
for the development of early cerebral edema at admission in-
clude hyperdense artery sign, elevated blood glucose levels, 
decreased level of consciousness, and signs of the extent of 
early ischemic changes on CT at baseline.59,60
Circulati g serum markers associated with the deterioration 
of BBB integrity and predictive of cerebral edema have been 
examined.1 Matrix metalloproteinase-9 is a key BBB-degrading 
enzyme that is highly expressed following stroke and has dem-
onstrated a deleterious role in stroke outcome.61,62 In patients 
with massive MCA infarction, a threshold of ≥140 ng/mL was 
predictive of malignant progression with 64% sensitivity and 
88% specificity.23 However, matrix metalloproteinase-9 is a 
nonspecific marker of inflammation,63 with elevated levels also 
found in other conditions.63–66 Serum cellular fibronectin—
a constituent of the basal lamina—has been investigated for 
its ability to predict edema; a threshold of >16.6 µg/mL pre-
dicted the development of edema.23 Similarly, increased protein 
S-100β levels—a calcium-binding protein—were identified in 
circulation after ischemic stroke and correlated with volume of 
infarction, stroke severity, and functional outcome.7,67 Elevated 
levels of SUR1—a potential biomarker—in the cerebral spinal 
fluid are associated with edema on CT and precede the peak in 
intracranial pressure.68 Conversely, decreased levels of SUR1 
between 48 and 72 hours are associated with improved cerebral 
edema and clinical outcome.68 Other markers of cerebral edema 
are under investigatio , but to dat , none have demonstrated 
sufficient robustness for routine clinical practice, and a com-
bined approach using some or all novel biomarkers of edema 
with diagnostic accuracy is yet to be established.
Figure 2. Stages of cerebral edema. A, Cytotoxic edema. Disruption of ce-
rebral blood flow that occurs during vessel occlusion depletes the energy 
supply to cells such as astrocytes and neurons. As cellular ATP concentra-
tions decrease, active transport channels are impaired allowing an influx of 
ions, predominantly sodium, and water following, into cells causing them 
to swell. B, Ionic edema. Depletion of solutes in the brain parenchyma 
creates an osmotic gradient pulling ions from the endothelium to the brain 
extracellular space. C, Vasogenic edema. Swollen cells eventually rup-
ture and release cellular contents into the brain parenchyma. Disruption 
of the endothelial tight junctions and blood-brain barrier (BBB) permit the 
movement of proteins, solutes, and water into the parenchymal space and 
worsen edema.
Downloaded from http://ahajournals.org by on February 7, 2020
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As illustrated in figure 7, a final result in the increasing permeability of the BBB due to 
ischaemic damage can be haemorrhagic transformation, in which a severe damage to 
capillaries and arterioles causes extravasation of all blood constituents, including red blood 
cells, into the parenchyma [36, 50, 46]. Thus haemorrhagic transformation is associated with 
a more severe disruption of the BBB [40]. 
 
Figure 7. Transvascular oedema of increasing severity, resulting in haemorrhage. This 
process is driven by progressive degradation of the endothelial cells until they meet oncotic 
cell death. Ionic oedema, created by cytotoxic oedema of the endothelial cells and 
transcapillary flux of Na+, is mediated by channels and transporters. In vasogenic oedema, 
plasma proteins but not erythrocytes exit from the vessel through transcellular channels, 
degradation of tight junctions and endothelial retraction. In haemorrhagic transformation, 
erythrocytes can exit the vessel through a ruptured endothelium and vessel wall structures. 
From Stokum et al. [40]. Reproduced with permission. Copyright 2016 SAGE Publications. 
 
1.3.2 tPA 
IVT with recombinant tissue plasminogen activator (tPA), alteplase, triggers fibrinolysis by 
activating plasminogen to plasmin, an enzyme that splits fibrin, which results in in clot 
disruption [51]. The aim is to dissolve the blood clot and achieve recanalization as soon as 
possible. The drug is given as an infusion oven 1 hour.  
IVT is associated with a risk of intracerebral haemorrhage (ICH). This is an important 
complication of ischaemic stroke, particularly in patients that receive IVT where the risk of 
haemorrhage is increased after administration of IVT. However, IVT in itself also increases 
the risk of haemorrhage. The frequency of symptomatic ICH (SICH) after IVT is between 2-
7% depending on the definition of SICH [52]. From published studies in humans, there is no 
 
Figure 3. Phases and select mechanisms of endothelial dysfunction. In ionic edema, water
flux (blue arrows) and ion flux (grey arrows) are mediated by plasmalemma channels and
transporters; vasogenic edema, which includes extravasation of plasma proteins, but not
erythrocytes, is mediated by transcellular channels, MMP degradation of tight junctions,
and endothelial retraction, phenomena that are, in part, triggered by VEGF, Ang2, and
CCL2 signaling; hemorrhagic transformation occurs due to structural failure of the vessel,
Article Copyright © 2015 Authors, Sourc  DOI: 10.1177/0271678X15617172.
See content reuse guidelin s at: sagepub.com/journals- ermissions
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definite clinical evidence that the risk of COED is increased by IVT. A meta-analysis, 
compiling six smaller studies, did not find IVT a statistically significant predictor for cerebral 
oedema [53]. 
1.3.3 Experimental treatment: imatinib 
Animal studies have suggested that IVT using alteplase disrupts the BBB, thus increasing the 
risk for both COED and haemorrhage [54].  
In the late 1990s, researchers at Karolinska institutet isolated new members of the platelet-
derived growth factor (PDGF) family, a group of growth factors [55]. One of these factors, 
PDGF-CC, is produced in several tissues, including the brain. In order to be able to bind to its 
cellular receptor, the PDGF-receptor-alpha, PDGF-CC must first be activated by tPA [56]. 
Further experimental studies showed that activation of PDGF-CC with tPA is an important 
mechanism for regulation of the BBB integrity. In stroke, this mechanism is activated, 
potentially leading to oedema and haemorrhage in the brain. Imatinib, a tyrosine kinase 
inhibitor, blocks the signalling of PDGF-receptor-alpha on perivascular astrocytes. In 
experimental stroke models, imatinib was shown to significantly reduce BBB permeability, 
oedema and haemorrhagic complications in thrombolytic tPA treatment. PDGF-CC levels 
were increased in the plasma of ischaemic stroke patients after thrombolytic tPA treatment 
and higher levels of PDGF-CC were associated with an increased risk of haemorrhagic 
transformation. Based on these and other results, it was hypothesized that by blocking PDGF-
CC mediated signalling in ischaemic stroke with imatinib, a substantial reduction of oedema 
and haemorrhage, and their resulting brain injury, could be achieved [41]. 
Imatinib is commercially available as a drug for long-term treatment of haematological 
cancer. It is available as tablets, 100 mg and 400 mg. The dose range for treatment within 
oncology is between 400 and 800 mg daily. Doses up to 1000 mg have been examined in 
pharmacokinetic studies. The average bioavailability is 98% with high variability between 
patients.  
1.4 CEREBRAL OEDEMA IN ANTERIOR CIRCULATION ISCHEMIC STROKE 
The presence of COED (as measured by MRI) independently predicts worse outcome in all 
including smaller ones [57]. However, it is in large infarctions that the effect is most 
pronounced. 
1.4.1 Large hemispheric infarction and malignant MCA infarction 
The term large hemispheric infarction (LHI) describes a large cerebral infarction that affects 
most of, or the whole, MCA territory, with or without additional vascular territories. It occurs 
in patients with anterior circulation LAO who have an occlusion is situated in the ICA or 
MCA, with or without involvement of ACA or PCA [58, 48]. Less than 10% of patients with 
AIS develop LHI [48]. Clinical symptoms and signs include contralateral hemiparesis, 
contralateral sensory loss, aphasia, inattention and neglect, hemianopia or gaze deviation. 
Patients usually have a NIHSS score of more than 16-20 in the dominant hemisphere and 15-
 12 
18 in the nondominant hemisphere [59, 60]. The risk of life-threatening COED in LHI is 
reported to be more than 50% [48]. However, various definitions of LHI have not been 
entirely consistent. 
A recent guideline from the German Neurocritical Care Society provided a definition of LHI 
as "a large ischaemic stroke affecting the total or subtotal territory of the MCA, involving the 
basal ganglia at least partially, with or without involvement of adjacent ACA or PCA 
territories" [58]. This definition is similar to "malignant" MCA infarction, a term that was 
introduced by Hacke et al. in the 1990s [61, 62] and refers to a large and potentially life-
threatening infarction in the MCA territory, with or without involvement of additional 
vascular territories. Although the term "malignant" MCA infarction is widely used, there is 
no generally accepted definition [44, 60, 63].  
 
 
Figure 8. Tissue shifts created by a space-occupying large hemispheric infarction (LHI), for 
example a large middle cerebral artery infarction. A. The brain swelling initially causes 
compression of a ventricle and initial midline shift in the direction of the most easily yielding 
structures. B. As these become compressed, their ability to yield further decreases, and 
increasing pressure results in transtentorial herniation. From Steiner et al. [66]. Reproduced 
with permission from Springer Nature Customer Service Centre GmbH. Copyright 2001 
Springer Nature. 
 
Please see figure 8 for a schematic drawing of a space-occupying LHI leading to tissue shifts. 
When transvascular oedema develops, the swollen part of the brain pushes on its 
surroundings, causing tissue shifts. The swelling is initially counteracted by a decrease of 
intracranial blood volume and cerebrospinal fluid (CSF) but if these adaptive mechanisms are 
exhausted, the intracranial pressure starts to rise [64]. As a consequence of continued 
swelling, in the anterior circulation, ischaemia and tissue shifts are worsened leading to 
transtentorial and uncal herniation and subsequent brainstem damage [65, 44]. During this 
Increased Intracerebral Pressure Following Stroke Steiner et al. 443
Contr indications Pulmonary edema, congestive heart failure, decreased renal function, dehydration, 
hyperosmolalic coma, and hemolytic anemia.
Main drug interactions None.
Main side effects Nausea and vomiting, diarrhea, hemoglobinuria, bleeding diathesis, hemolysis, 
acute renal failure, and oxalosis.
Special points Glycerol is more effective if administered via the enteric route. Occurrence 
of rebound intracranial hypertension is controversial. Glycerol has a shorter 
duration of action than mannitol because of greater brain penetration 
and tubular re-absorption.
Cost/cost effectiveness No data available.
Figure 1. Increased intracranial pressure with consecutive herniation due to a space-occupying middle cerebral artery infarction. 
A, initial compression of the side ventricle. B, increasing intracranial pressure leads to transtentorial herniation.
Figure 2. 19-year-old woman with acute, high-grade, left-sided hemiparesis due to cardioembolic stroke. A, carotid compression 
tomography (CCT) 3 hours after the first symptoms, which reveals large middle cerebral artery (MCA) territory stroke of the right 
hemisphere. B, CCT on day 1 with large MCA stroke signs of the beginning of hemispheric swelling (compression of the lateral 
ventricle, slight midline shift). At this time, the patient’s consciousness started to decline and the hemiparesis had become worse. 
C, postoperative CCT, which demonstrates the decompressive effect by brain tissue herniating through the craniotomy.
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process, the patient suffers from progressive symptoms of a space occupying intracranial 
process (headache, vomiting, reduced level of consciousness) and eventually death. 
 
A time course of maximum cerebral oedema between the third and fifth day after after stroke 
onset has been confirmed in several studies [67]. In an autopsy study 1959, Shaw et al. [68] 
observed that the midline shift was largest in patients with MCA infarctions that died 
approximately 4 days after stroke onset, indicating that the swelling peaked at that time point. 
Please see figure 9. Previous to that, the clinical appearance of large oedema after cerebral 
infarction had been described in detail, for example by Scarcella et al. who also described the 
radiological appearance, with midline shift, using pneumoencephalograms [69]. Later work 
continued to combine data from necropsy and radiology to describe time course and 
pathological macroscopic appearance [70-73].The neurological deterioration related to 
cerebral oedema after a large MCA infarction usually starts within 48 hours after onset of 
stroke symptoms but with even earlier deterioration, within 24 hours, seen in up to one third 
of patients [74]. Hacke et al. [61], who measured midline shift on CT, observed that maximal 
midline shift occurred between day 2 and day 4 in patients that died but between day 3 and 
day in survivors.  
 
 
Figure 9. Autopsy data on the time course 
of brain swelling in 28 fatal cases of middle 
cerebral artery (MCA) infarction. Midline 
shift at post-mortem examination is plotted 
against the time between stroke onset and 
death. The figure shows that for most cases 
that died during the first 20 days, the 
midline shift at death fits a curve with 
maximum at 4 days. From Shaw et al. 1959 
[68]. Reproduced with permission. 
Copyright 1959 American Medical 
Association. 
 
If treated conservatively, approximately 70% of patients with a large infarction and 
expanding COED in the territory of the MCA territory will have died within 6 months [75, 
76]. COED is a cause of death in 5% of all patients with hemispheric infarction [73, 77]. In a 
study performed among 1073 consecutive stroke patients before modern reperfusion 
therapies, Silver at al. [73] described that early mortality after stroke has a bimodal 
distribution: one peak occurs during the first week, and a second during the second and third 
Case 17 illustrates some of the difficulties
encountered in determining the duration of
the major infarction. Three years before
death the patient had a "stroke," with left
hemiplegia. Thirteen days before admission
he became drowsy and lethargic, and again
developed a complete left hemiplegia. Two
days before admission he became comatose
and on admission was noted to be lethargic
and to have a left hemiplegia involving
the face, as well as the extremities. He
died 13 days later. Multiple areas of soften¬
ing were present, the oldest, in the right
side of the pons, being consistent with the
old left hemiplegia; a recent area of soften¬
ing in the right caudate nucleus, seen
microscopically, was consistent with the
four weeks' duration of recurrent left
hemiplegia with drowsiness, but the necrosis
of the right cerebral cortex in the distribu¬
tion of the middle cerebral artery seemed
considerably more recent, since no gitter
cells had developed, there were neutrophilic
leukocytes and microglia about blood ves¬
sels, and the neurons were still visible and
demonstrated ischemie changes. Although it
was originally thought that the duration was
26 days, the microscopic appearance
strongly suggests that the massive cortical
infarction was of much shorter duration,
probably less than 1 week, even though
there was no dramatic clinical correlate dur¬
ing his two weeks of observation in the
hospital.
Four patients (Cases 15 to 18) reported
by Berry and Alpers6 died after 12 days
to 2 months. Their clinical and postmortem
data are summarized in Table 2.
Cases of over three months' duration
were not included because of difficulty with
postmortem preservation of the surface of
the brain, thus making it impossible to
measure the degree of shift toward the
atrophie lesion.
Comment
A. Pathology.—One of the major goals
of this investigation has been the determina¬
tion of the frequency and the temporal
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Fig. 3.—Time course of swelling of ischemieinfarction in the distribution of the middle cerebral
artery in cases of sudden onset with accurately
known duration and with demonstrated arterial oc¬
clusion. Dashed lines indicate 2 mm. variation from
the curve.
course (development and subsidence) of
swelling with cerebral infarction. In order
to make the series as complete as possible,
the literature was reviewed and all similar
cases summarized in Table 5. From the 69
cases, which include the 17 cases presently
reported (Table 1) and 15 of the cases
previously reported by Berry and Alpers 6
and summariz d in Table 2, were selected
those cases which would best demonstrate
the temporal course of swelling with a rela¬
tively simple cerebral infarction.
Since it seemed likely that the amount of
swelling would be directly related to the
size of the infarct, and possibly also to
Fig. 4.—Time course of swelling of massiveencephalomalacia in cases not completely fulfillingthe criteria for inclusion in Figure 3 (see text).Dashed lines indicate 2 mm. variation from the
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weeks. Of the 125 patients with ischaemic stroke that died, 46 patients died during the first 
week and majority or 78% (36/46) of those patients died of transtentorial herniation.  
1.4.2 Detection of cerebral oedema in ischaemic stroke 
The most common method used today is neuroimaging. Since attenuation of X-rays correlate 
with the tissue´s water content, CT detects ionic oedema with a high specificity but does not 
detect cytotoxic oedema [78, 79]. Cytotoxic oedema, in which cell swelling decreases 
diffusion of water molecules in the extracellular space, can be detected with diffusion-
weighted MRI. Vasogenic oedema can be detected with CT or MRI [80, 79]. Details on 
radiological classification of COED can be found in Subjects and Methods. Transcranial 
sonography, which displays the brain parenchyma and ventricular system through the skull, 
may be used to detect midline shift secondary to mass effect. However, this is not routinely 
done [81]. Shift in CSF volume has been proposed as a measurement of oedema severity; a 
decrease in volume correlated with infarction volume and maximal midline shift [82]. 
1.4.3 Predictors for cerebral oedema 
Hofmeijer et al. [53] summarized research on predictors until 2004. They found 23 cohort or 
case-control studies published between 1998 and 2004 that fulfilled criteria for inclusion in a 
meta-analysis of predictors for life-threatening COED. Of 27 factors evaluated for the meta-
analysis, 12 proved to statistically significant associations. The strongest predictors for the 
development of life-threatening COED were mechanical ventilation, a large infarction size 
and large perfusion deficit. For infarction size, the increase in risk was dependent on different 
cut-offs used in the individual studies, from 50% to 100% of the MCA territory, larger 
infarction corresponding to higher risk. Other, weaker but still statistically significant, 
predictors for life-threatening COED were early mass effect, involvement of more than one 
vascular territory in addition to MCA, higher body temperature at admission and ICA 
occlusion. A paradoxical finding was that MCA occlusion was associated with a lower risk of 
life-threatening COED; however, this finding was explained as a result of over-representation 
of patients with occlusions of the distal parts of the MCA. In a narrative review, Hofmeijer et 
al. also summarized 11 studies from 1998 to 2004 for reported factors that could not be 
included in the meta-analysis. Higher stroke severity scores, measured by NIHSS and the 
Scandinavian Stroke Scale, were associated with a higher risk for life-threatening COED. 
Their main conclusion was that the risk for life-threatening COED seems to be strongly 
associated with increased infarction size. Evidence for this was an association with 
radiologically detected infarction size and with proxies of infarction size such as the need for 
mechanical ventilation, large perfusion deficit, involvement of more than one vascular 
territory and ICA occlusion. However, the authors noted limitations to their conclusions, the 
most important being a large variety of inclusion criteria and methods among the included 
studies. Therefore, the predictive values for life-threatening COED were generally moderate 
and depended on the incidence of oedema which varied between included studies. 
Furthermore, only studies of severe MCA infarction were included. 
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A post-mortem study provided more evidence that female sex and younger age, together with 
abnormalities of the circle of Willis, are predictors for a malignant course in COED [83]. In a 
Finnish cohort of 943 patients treated with IVT, higher baseline NIHSS score, presence of 
hyperdense artery sign (HAS) or signs of early infarction on CT, and longer onset-to-
treatment time for IVT time were all associated with development of COED [84] 
In clinical practice, to monitor patients at risk for life-threatening cerebral oedema, repeated 
neuroimaging is done to follow the clinical course [59]. Attempts have been made to quantify 
the value of radiology for prediction of a malignant outcome using CT, CT angiography, CT 
perfusion or MRI. One strategy has been to use size as a predictor. Using MRI, a DWI 
volume of more than 82 cm3 within 6 hours after onset, or 145 cm3 on within 14 hours, 
predicts a malignant course [85-87]. MRI has the potential to provide information for 
prediction of malignant MCA infarction also in older patients [88]. Measurements of BBB 
permeability have been used for prediction of a malignant course, using CT, MRI and 
SPECT, although with moderate success [89, 90]. Hyperdense MCA has been shown to 
predict a malignant MCA infarction [91-93]. The inter-caudate distance on MRI, an indicator 
of brain atrophy, may be used by itself or in combination with DWI volume to predict a 
malignant outcome [94, 95]. In one study, the ratio of ischaemic lesion volume to CSF 
volume seemed to predict the development of malignant MCA infarction [96]. Multimodal 
monitoring including physiological methods, laboratory tests, cerebral microdialysis methods 
and EEG have been used in attempts to predict malignant MCA infarction [97-99]. In one 
study, a marker of BBB disruption (plasma c-Fn) was associated with malignant MCA 
infarction and in other studies S100 levels have been associated with larger volume of 
infarction, or space-occupying MCA infarction [100-102]. A method of correlation between 
systolic blood pressure and intervals between heartbeats was used to measure baroreflex 
sensitivity, which was decreased in patients with large stroke who are at risk for a malignant 
outcome [103]. EEG and brain stem auditory evoked potentials were evaluated in a small 
study and found to be somewhat predictive of malignant MCA infarction [104].  
Several studies have presented multivariate models with adjustment for background factors. 
Among patients with large MCA infarctions, an increased risk of fatal cerebral oedema was 
associated with history of hypertension or heart failure, increased baseline white blood cell 
count, major early CT hypodensity involving 50% of the MCA territory, and involvement of 
additional vascular territories [105]. Among patients with MCA infarctions with baseline 
NIHSS 20 (left-sided) or 15 (right-sided) within 6 hours of symptom onset, nausea/vomiting 
or 50% MCA territory hypodensity are risk indicators for developing fatal brain swelling 
[106]. A clinical score, the DASH score, was developed to assess risk for development of 
malignant MCA infarction in patients with large vessel occlusion [107]. The DASH score 
consists of the following parameters: 1 point for large infarction, defined as Alberta Stroke 
Program Early Computed Tomography Score (ASPECTS) ≤3 on diffusion-weighted MRI, 1 
point for infarction in the territory of the anterior cerebral artery, 1 point for occluded MCA 
and 1 point for hyperglycaemia. More than 90% pf patients with a DASH score of ≥3 
developed a malignant MCA infarction. In another study, a combination of MRI with six 
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hours after symptom onset and NIHSS after 24 hours was used to predict malignant MCA 
infarction [108].  
1.5 TREATMENT OF CEREBRAL OEDEMA IN ISCHAEMIC STROKE 
1.5.1 Medical management 
The usefulness of medical management for COED is not established [109, 110]. There is no 
evidence from observational studies or randomized trials that drugs that lower the intracranial 
pressure with osmotic therapy also improve outcome in patients with COED [59, 44, 109, 
46]. As osmotic therapy with mannitol or saline quickly lowers the intracranial pressure, this 
treatment may be used in an acute setting, in patients that deteriorate [111, 46]. Osmotic 
therapy does not have sufficient long-term effect in space-occupying infarctions. Similarly, 
corticosteroids or hypothermia have no proven effect [111]. 
1.5.2 Decompressive surgery in anterior circulation stroke 
Decompressive hemicraniectomy (DHC) with duraplasty is a surgical procedure where a 
bone flap with a diameter of usually more than 12 cm is removed allowing the brain to swell 
outwards [59, 112-114]. 
Randomized trials have shown that early DHC reduces mortality and has a positive effect on 
functional outcome in patients with malignant MCA infarction [115, 116, 86, 117-122]. 
Three RCTs published in 2007-2008 showed that early (within 48 hours) surgical treatment 
significantly reduces mortality without increasing severe disability in patients 60 years or 
below [115, 116, 86, 117, 123]. When pooled together, data from 93 patients showed that 
numbers needed to treat (NNT) were 2 for survival with a mRS score ≤4, 4 for survival with 
a mRS score ≤3, and 2 for survival irrespective of outcome, at one-year follow-up [116]. 
There was also a positive effect on functional outcome in this age group. Criteria for early 
DHC are radiological evidence of a large MCA (and any additional vascular territory), 
NIHSS ≥20 (dominant hemisphere) or ≥15 (non-dominant hemisphere) and impairment of 
consciousness. Based on one of the randomized trials, involvement of the basal ganglia is 
regarded as a negative prognostic sign for severe oedema which strengthens the indication for 
surgery [124, 115, 125]. In a meta-analysis of randomized trials, functional outcome among 
122 patients at 6 months were as follows, scored using the modified Rankin scale (mRS): 
20% mRS 2-3 (no mRS 0 or 1), 36% mRS 4, 18% mRS 5 and 26% mRS 6 (dead) [76]. Data 
from a randomized clinical trial (DESTINY II) suggest that hemicraniectomy has a life-
saving effect also in patients aged 61 years or more, based on approximately the same criteria 
as above, although the effect on functional outcome is less certain [121]. 
DHC is recommended in clinical guidelines. Most patients treated with DHC for space-
occupying have a reasonable quality of life at long-term follow-up [126, 127]. Complications 
after DHC include: sinking skin flap syndrome, fluid collections, hydrocephalus, epidural or 
subdural hematomas, infections and skin or muscle necrosis [128-130, 125] 
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2 AIMS 
2.1 GENERAL AIM 
The aim of this doctoral thesis was to contribute to the understanding of clinical, radiological 
and treatment aspects of cerebral oedema (COED), in patients with ischaemic stroke.  
2.2 SPECIFIC AIMS 
Paper I 
To establish the most important predictors for the occurrence of early (22-36 h) COED in 
ischaemic stroke patients receiving intravenous thrombolysis (IVT), using data from the SITS 
Registry. In particular, to determine baseline clinical and radiological parameters that predict 
development of early COED, as defined by neuroimaging. A secondary aim was to study the 
association of early COED with long-term functional outcome and death.  
Paper II 
Test the hypothesis that, in patients with anterior circulation stroke due to large artery 
occlusion (LAO), recanalization observed at 22-36 hours decreases the risk for moderate to 
severe COED observed at the same time point. A secondary aim was to investigate the effect 
of recanalization on short-term and long-term outcomes (death, functional outcome).  
Paper III 
Perform a phase 2, pilot, randomized trial of oral imatinib versus control in ischaemic stroke 
patients after IVT and report the results regarding safety and effect on outcomes.  
Paper IV 
To evaluate the clinical characteristics, including affected side, and outcomes of 
decompressive hemicraniectomy (DHC) in patients with anterior circulation stroke in the 
SITS Registry. In addition, to compare functional outcome and death in this population to 
published randomized controlled trials of surgical treatment for space-occupying large 
hemispheric infarction (LHI), both overall and in relation to age.  
 

  19 
3 SUBJECTS AND METHODS 
3.1 OVERVIEW OF PAPERS 
 
 Paper 
Characteristic I II III IV 
Organizer of data 
collection 
SITS Registry SITS Registry iStroke Pilot 
Study 
SITS Registry 
Setting  Hospitals in 
41 countries 
Hospitals in 
62 countries 
5 hospitals 
Stockholm 
Region 
Hospitals in 
35 countries 
Study period 2002-2011 2002-2017 2011-2014 2008-2019 
Design Observational Observational Randomized 
open-label 
Observational 
Study population Stroke patients 
that received 
IVT 
Stroke patients 
with imaging 
signs of arterial 
occlusion, 
had IVT and/or 
EVT 
Stroke patients 
that received  
IVT 
Stroke patients 
that underwent 
DHC  
Number of patients 42 187 22 184 60 684 
Main predictor(s) Baseline 
variables 
Recanalization 
at 22-36 hours 
Oral imatinib 
for 6 days 
Baseline 
variables 
including age 
Main outcome(s) COED,  
ICH,  
mRS, death 
 
COED,  
ICH, 
mRS, death 
Primary:  
Adverse events, 
death 
Secondary:  
ICH, COED, 
NIHSS,  
mRS, death 
mRS, death 
Table 1. Overview of papers.  
Abbreviations: cerebral oedema (COED), decompressive hemicraniectomy (DHC), 
endovascular thrombectomy (EVT), intracerebral haemorrhage (ICH), intravenous 
thrombolysis (IVT), modified Rankin scale (mRS), National Institutes of Health stroke scale 
(NIHSS) 
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3.2 PAPER I, II AND IV 
Flow diagrams showing the selection of study populations for paper I, II and IV can be found 
in figures 10, 11 and 12. 
 
 
Figure 10. Flow diagram for paper I. 
Abbreviations: Cerebral oedema (COED), endovascular thrombectomy (EVT), intravenous 
thrombolysis (IVT), modified Rankin Scale (mRS). 
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Figure 11. Flow diagram for paper II. Abbreviations: Cerebral oedema (COED), 
endovascular thrombectomy (EVT), intravenous thrombolysis (IVT), modified Rankin Scale 
(mRS). 
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Figure 12. Flow diagram for paper IV. Abbreviations: Decompressive hemicraniectomy 
(DHC), modified Rankin scale (mRS) 
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3.2.1 The SITS Registry  
Paper I, II and IV report observational studies in which patients were collected from the Safe 
Implementations of Treatments in Stroke-International Stroke Treatment Registry (SITS-
ISTR), also called the SITS Registry. This is a prospective, internet-based, academic-driven, 
multinational stroke register. The SITS Registry is an academic-driven, non-profit, 
international collaboration. The web site is www.sitsinternational.org.  
The SITS Registry collaboration has 2 main levels of organization: individual centres, which 
usually are equivalent to hospitals, and countries. A centre can participate in the SITS 
Registry, under the responsibility of the local coordinator, after authorization by the local 
head of the department. The local coordinator for the SITS Registry is normally the person in 
charge of acute stroke care at the centre and is responsible for, and verifies, that data is 
completely and accurately collected according to protocol. The local coordinator is usually a 
stroke physician. In addition, there is usually at any given centre a local team of investigators 
that can enter data into the registry. Furthermore, every country has a national coordinator, 
usually a senior stroke researcher, appointed by SITS International. The national coordinator 
has access to all data from that country and has a supporting role for the centres of that 
country. SITS International has a Scientific Committee, consisting international stroke 
researchers, that oversees all scientific activities and projects based on the SITS Registry 
database. The SITS Scientific Committee approved the research plans for paper I, II and-III, 
which are all based on SITS Registry data, before data analysis was started. 
The SITS Registry currently has several different data entry protocols with different 
purposes. There is, however, a core list of data collection that is identical between most of 
these protocols. Upon participation, a centre agrees to register data according to one or more 
of these protocols. The following protocols were used in varying degrees for paper I, II and 
IV: IVT Standard Protocol, IVT Minimal Protocol, Thrombectomy Protocol, All Patients 
Protocol Standard and All Patients Protocol Minimal. Two other protocols, SITS Quality 
Registry and SITS Intracerebral Haemorrhage Registry (SITS-ICH), were not used.  
By formal agreement between SITS International and both national and local coordinators, a 
centre is required to accept consecutive registration of all patients according to data entry 
protocol. For example, if the centre registers only patients treated with intravenous 
thrombolysis and use the IVT Standard Protocol for data entry, then the centre has to register 
all patients with stroke symptoms receiving IVT irrespective of whether treatment was on- or 
off-label. If the centre registers all stroke patients in the registry, using All Patients Protocol, 
consecutive registration of all patients with stroke diagnosis is obligatory.  
Data in the SITS Registry are entered on-line through the SITS website. Every investigator 
logs in through a 2-way authentication system, a personal access code which must be kept 
secret and used only by the owner and an e-mail or SMS verification code. All data entry 
from a centre can be made by each member of the local team, but once the data entry is 
confirmed (and cannot be changed), the person who made the confirmation will be identified 
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on the data entry form. The current SITS registry is developed, maintained and upgraded by 
Zitelab, Copenhagen, Denmark, in collaboration with SITS. For the purpose of scientific 
publication, a download is made in Excel/CSV format which then is transferred to statistical 
analysis software, for example Stata.  
3.2.2 Subjects 
All patients in paper I, II and IV had presumed ischaemic stroke, were admitted to a hospital 
and given whatever routine treatment that was best practice at that hospital. Patients may also 
have been referred to secondary or tertiary hospitals for surveillance or treatment.  
3.2.3 Data collection 
Data was collected and entered into the registry by local investigators at each hospital. The 
SITS Registry protocols recommend that data is to be registered from certain points in time 
during hospitalization and follow up. The following list includes data that was used for paper 
I, II and III, with time points counted from initiation of first treatment (IVT or EVT): 
• At baseline: demographic data, pre-stroke mRS, medical history including 
comorbidities, risk factors and concomitant medication, date and time of stroke onset, 
date and time of admission, NIHSS score including sub-items, systolic and diastolic 
blood pressure, laboratory values (for example blood glucose, total level of 
cholesterol, APTT), imaging scans (CT and/or MRI) with date and time of 
examination. 
• At 2 hours: NIHSS score including sub-items, systolic and diastolic blood pressure 
• At 24 hours: NIHSS score including sub-items, systolic and diastolic blood pressure, 
imaging scans (CT and/or MRI) with date and time of examination (allowed time 
interval between 22 and 36 hours).  
• During the hospital stay: details of concomitant medications, any additional imaging 
scans, treatments given (EVT, DHC, stroke unit care) and some details of treatments  
• At 7 day or at discharge, whichever comes first: date and time of discharge, NIHSS 
score including sub-items, systolic and diastolic blood pressure, type of stroke, any 
atrial fibrillation, medications.  
• At 3-months follow up, done at 90 days plus or minus 10 days: mRS score, any new 
events including recurrent stroke (haemorrhagic or ischaemic).  
• Whenever appropriate: date and time of death 
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3.3 PAPER III 
Please see flow diagram of the iStroke Pilot study in figure 13. 
 
Figure 13. Flow 
diagram of the 
iStroke Pilot Study 
reported in paper 
III. 
 
3.3.1 The iStroke Pilot study 
The iStroke Pilot study was a prospective, randomized, open, blinded evaluation, ascending-
dose pilot trial of oral imatinib in acute ischaemic stroke. The primary objective was to 
evaluate the safety and tolerability of imatinib when administered in patients treated with IVT 
in AIS. The secondary objective was to evaluate the efficacy of imatinib when administered 
in patients treated with intravenous thrombolysis in acute ischaemic stroke. Since the goal 
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was to evaluate a drug by giving it to patients that had the health condition of interest, while 
monitoring safety, it was a phase 2 study [131]. As it was a small-scale evaluation of the 
feasibility of study methodology, in preparation for a larger study, it was also called a pilot 
study [131].  
The primary endpoints, regarding safety, were the following: 
• Serious and non-serious adverse events (in particular those listed as reported adverse 
events in long-term treatment with imatinib for oncological indications). 
• Mortality. 
• Laboratory values, in particular blood cell count, bilirubin, aspartate aminotransferase 
(ASAT), alanine amonotransferase (ALAT), amylase and creatinin. 
 
According to the protocol, secondary endpoints for efficacy were: 
• Occurrence and severity of haemorrhagic transformation, or intracerebral 
haemorrhage on post-treatment CT or MRI. 
• Occurrence and severity of COED on post-treatment CT or MRI. 
• Neurological outcome at 2 h, 24 h and 7 days. 
• Functional outcome at 3 months. 
 
Patients were recruited at 5 hospitals in the Stockholm Region between 2011 and 2014. 
Patients who met routine criteria for intravenous thrombolysis were screened for the study as 
soon as possible after initiation of IVT. If inclusion criteria were met, and informed consent 
was obtained, the patient was randomized to either imatinib or no imatinib treatment. The 
randomization was done not later than 1 h after completion of IVT, or, if applicable, within 1 
h after completion of EVT. Administration of oral imatinib was done as soon as possible after 
randomization. Tablets were preferably taken with a glass of water. In case of difficulties to 
swallow, tablets could be dissolved in in a fluid and, if needed, administered through 
nasogastric feeding tube. The acute treatment period was 6 days. 
In the first part of the study, a dose of 400 mg imatinib was given, followed by a second step 
with 600 mg and a third step with 800 mg. Before any increase of dose was initiated, an 
independent safety committee had to decide that no safety issues, that would motivate a 
termination of recruitment, had occurred. Each of the 3 parts of the study included 15 patients 
that were treated with imatinib and 5 patients that received no treatment. Randomisation was 
done through an interactive web system (Viedoc). 
Table 2 gives a summary of the major investigational events according to the study protocol. 
Patients were followed at the hospital ward during the study period. CT scans were 
performed before initiation of IVT and 22-36 hours after IVT, according to the standard 
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clinical protocol. MRI examinations were performed, as a part of the study procedures, within 
the same interval as the follow-up CT (22-36 h post IVT initiation) and at day 7. CT and MRI 
examinations were evaluated blindly by two experienced neuroradiologists to reach a 
consensus.  
 
 
Event 
Day 
0 1 2 3 4 5 6 7 90‡ 
Brain CT Before start 
of IVT 
22-36 h 
after IVT 
      X†  
Brain MRI  22-36 h 
after IVT 
     X  
Informed  
consent and 
randomization 
Within 1 h 
after end of 
IVT or EVT 
        
Administration 
of treatment drug 
(oral imatinib) 
Immediately 
after 
randomization 
X X X X X    
Blood sample  
for imatinib 
concentration 
3 h after  
first dose  
of imatinib  
X X       
Blood sample  
for other lab tests 
X X      X X 
Blood pressure  X* X X X X X X X X 
Registration of 
adverse events 
X X X X X X X X  X§ 
NIHSS scoring  X* X X X X X X X  X§ 
mRS scoring X       X  X§ 
Table 2. Major investigational events of the iStroke Pilot Study (paper III), from day 0 (the 
day of inclusion) to final follow-up at 90 days (3 months). 
* Done both before and 2 h after start of IVT 
† CT on day 7 was optional 
‡ Final follow-up between day 85 and day 100 (3 months).  
§ At final follow-up, the investigator was blinded to treatment status. 
 
Patients were followed for 3 months after stroke onset. The final follow-up and evaluation 
was done between day 85 and day 100 with evaluations of the NIHSS and mRS scores by an 
investigator at a different hospital from the one responsible for the acute treatment. The 
investigator was blinded to treatment group. 
 28 
The study was conducted according to the Good Clinical Practice standard for clinical trials. 
Patient data was documented in a paper case record form and later transferred to electronic 
records for analysis. Adverse events, defined as any untoward medical occurrence in a study 
participant, were registered daily until day 7 and then at 3 months. Adverse events were 
classified by the investigator as related or not related to imatinib and furthermore classified as 
serious or non-serious.  
3.3.2 Subjects 
The most important inclusion criteria were:  
• Clinical diagnosis of acute ischaemic stroke causing a measurable neurological 
deficit. Ischaemic stroke was was defined clinically, as an event characterized by 
sudden onset of acute focal neurological deficit presumed to be caused by cerebral 
ischaemia, after CT scan had excluded haemorrhage  
• Neurological deficit with NIHSS score ≥7 at the time of randomization  
• Age between 18 and 85 years  
• IVT was indicated on clinical grounds and was initiated within 4.5 h of stroke onset  
• Patients were be competent to make a decision and has provided informed consent 
with regard to participation in the study, retrieval and storage of data and follow-up 
procedures  
The most important exclusion criteria were: 
• Severe stroke as assessed clinically (for example, NIHSS > 25) and/or developing 
extending into more than one third of the MCA territory or half of other vascular 
territories  
• Acute pancreatitis, severe hepatic dysfunction, including hepatic failure, cirrhosis, 
portal hypertension (oesophageal varices) and active hepatitis  
• Ongoing treatment with chemotherapy 
• Drugs that may increase och decrease the plasma concentration of imatinib  
• Contraindications against MRI  
3.4 CLINICAL ASSESSMENTS 
3.4.1 NIHSS 
The NIHSS is a 15-item scale that measures neurological impairment using components of a 
standard neurological examination [132, 133]. A person with no measured deficit scores 0. In 
theory the maximum score is 42, which in practice however is never reached. While 
originally designed to assess differences in treatments in clinical trials, it is today being used 
to clinically assess and follow patients in routine stroke care all over the world. NIHSS has 
overall high inter-rater reliability. Moreover, it has a high degree of validity in that the score 
correlates with volume [133]. However, because several of the items measure language-
related deficits, NIHSS measures the severity and size of strokes in the right hemisphere a 
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little differently than strokes in the left hemisphere. In a study that used CT to measure 
volume, median volume of a right hemisphere stroke was roughly equal to the median 
volume of a left hemisphere stroke in the next highest 5-point category of the NIHSS [134]. 
Thus, at a given NIHSS score, the median volume of right hemisphere strokes is larger than 
the median volume of left hemisphere strokes. 
3.4.2 Treatments 
In paper I, II and IV, treatments registered in the SITS Registry were used to different 
degrees. Treatments at baseline, that is to say treatments that were registered as being present 
at the time of stroke onset, were antiplatelet, statin, anticoagulant and antihypertensive 
treatment. Treatments given during the care of the patient were IVT, EVT, DHC and stroke 
unit care. Data on other treatments given during the care of the patients were not used when 
data was analysed.  
In paper III, treatments were registered according to the iStroke Pilot study protocol. 
Medications that could be registered as being present at the time of stroke onset were aspirin, 
warfarin, oral diabetic agents, insulin and statins. While all patients received IVT, any EVT 
or intra-arterial thrombolysis were registered. 
3.4.3 Functional outcome  
The modified Rankin scale (mRS), originally presented in 1957 and modified in 1988, is a 
commonly used scale used to assess disability in stroke patients [133, 135, 136]. The scale 
spans from 0 (no symptoms) to 6 (death) and contains the following grades [105]: 
• 0. No symptoms  
• 1. No significant disability, despite symptoms. Able to perform all usual duties and 
activities  
• 2. Slight disability. Unable to perform all previous activities but able to look after own 
affairs without assistance. 
• 3. Moderate disability. Requires some help, but able to walk without assistance.  
• 4. Moderately severe disability. Unable to walk without assistance and unable to 
attend to own bodily needs without assistance. 
• 5. Severe disability. Bedridden, incontinent, and requires constant nursing care and 
attention. 
• 6. Dead  
The scale is short which makes it relatively easy to use but also affects it reliability. To 
improve inter-rater variability, an approach based on rules or structural interviews is 
recommended [105]. 
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3.4.4 Death 
In paper I, II and IV, death of patients was registered through the variable for mRS in the 
SITS Registry, which was assessed at 3 months. Local investigators had an option to register 
a patient as alive, but with unknown mRS score, at 3 months.  
In paper III, which was a clinical study performed in accordance with Good Clinical Practice 
guidelines, death was registered by study investigators.  
3.4.5 Variables derived from NIHSS 
In paper I, II and IV, NIHSS item was 1a used to measure impairment of level of 
consciousness, which was defined as NIHSS item 1a scoring 1 or more, indicating a patient 
with decreased consciousness (not alert but arousable with different degrees of stimulation) 
or in coma. 
In paper II, 1 of the 4 subtypes of stroke defined by the Oxfordshire Community Stroke 
Project (OCSP) classification was derived from items of the NIHSS [67, 137]. The subtype 
Total Anterior Circulation Syndrome (TACS), which has a high compatibility with 
infarctions of the MCA territory, was used as a proxy for LAO involving the MCA territory 
[138, 139]. In the case of cerebral ischaemia, the OCSP classification correctly predicts the 
site of infarction in 75% of all patients, and slightly better in TACS where four of five 
patients (79%) are correctly classified [139]. TACS corresponds to large cortical MCA 
infarcts, involving the whole of the cortex supplied by the MCA plus white matter and at least 
part of basal ganglia, or infarcts of more than half of the MCA territory plus anterior cerebral 
artery ACA or PCA territory [139, 140]. The TACS subgroup consisted of patients with 
clinical characteristics of TACS according to the NIHSS, inferred when all the following 3 
criteria were met: first, aphasia (NIHSS item 9) or inattention (NIHSS item 11), second, a 
right or a left sensorimotor deficit (NIHSS items 4, 5, and 6) and, third, any visual defect 
(NIHSS item 3).  
In paper II, early neurological deterioration was defined as an increase in total NIHSS score 
of 4 points or more from baseline to 24 hours. 
In paper IV, baseline NIHSS items 5a and 6a (motor function of right arm and leg), 5b and 6b 
(motor function of left arm and leg) were used to infer right- or left sided hemiparesis while 
NIHSS item 9 for aphasia and item 11 for extinction/inattention were used to suggest 
localization of a lesion to the left or right hemisphere.  
3.4.6 Time intervals in the SITS Registry 
In the final follow up at 3 months, if mRS was missing then information on death was 
completed from several time points, such as date/time of death, outcome at 24 hours and at 7 
days. In paper II, onset-to-treatment time for IVT was derived from time of stroke onset and 
time of IVT administration. In paper IV, time from onset to neuroimaging was derived.  
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3.5 THE SITS COED SCALE 
In all papers of this doctoral thesis, the same 4-level ordinal scale is used to grade cerebral 
oedema. Since this scale was first being used in the SITS Registry, it is referred to as the 
SITS COED scale [141]. 
The SITS COED scale expresses brain swelling, as detected on CT or MRI, in thirds of the 
hemisphere, ignoring vascular territories. The scale has 4 levels, defined as follows:  
• No COED. 
• Mild COED. Focal brain swelling up to one third of the hemisphere. 
• Moderate COED. Focal brain swelling greater than one third of the hemisphere. 
• Severe COED. Brain swelling with midline shift.  
Please see figure 14 for examples. The term "focal brain swelling" remains undefined in the 
SITS protocol. In practice, however, signs of focal oedema are usually defined as narrowing 
of the CSF space, for example effacement (reduction) of cortical sulci or ventricular 
compression [142-144, 79].  
In general, radiological grading scales and guidelines for reporting cerebral oedema in acute 
ischaemic stroke usually consist of some of the following elements: extent of hypoattenuation 
and swelling, effacement of sulci and/or lateral ventricles, midline shift, effacement of basal 
cisterns and/or third ventricle and uncal herniation. This is based on research into the natural 
clinical and radiological course of cerebral infarcts that cause oedema [65, 142, 61, 144, 78]. 
According to von Kummer et al. in 1995 [143], the clearest way to express extent of 
parenchymal hypodensity may be as a proportion of the whole hemisphere. This was based 
on experience as no empirical evidence was presented. Elements of the scale were used in the 
ECASS 2 and the ECASS 3 trials, although not explicitly mentioned in the final publications 
[145, 146]. According to the study protocol of ECASS 3, investigators rated focal brain 
swelling ≤33% or >33% of the hemisphere, and furthermore graded focal brain swelling as 
"effacement of CSF space" or "midline shift". When the SITS-MOST Registry was started, 
the SITS COED scale was included in the study protocol in 2002 at the suggestion of the 
SITS-MOST study´s Brain Imaging Committee using that experience. The scale has been 
used by the SITS Registry ever since. Prior to this doctoral thesis, the SITS COED scale had 
been used in an analysis of local data from Helsinki [84].  
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Figure 14. Computed tomography (CT) images from the iStroke Pilot Study showing the 
development of a large infarction in the territory of left middle cerebral artery and 
development of cerebral oedema (COED), at different time points. At 25 hours, there is focal 
oedema and a slight ventricular compression (arrow). At 7 days a midline shift is visible 
(arrow). 
 
The reliability of the SITS COED scale has not been formally tested. However, in 1994 
Wardlaw et al. [142] published results regarding a 7-level cerebral oedema scale that provides 
indirect evidence. This scale was part of a score that classified radiological findings according 
to 3 variables: infarction size and location, swelling (oedema) and haemorrhage. The inter-
observer agreement for the cerebral oedema scale was excellent between experienced 
radiologists. The scale was subsequently used, for example in studies on reliability of early 
ischaemic signs and in the Third International Stroke Study [140, 147, 148]. When this 7-
level grading scale was abbreviated to only 3 levels, with some similarity to the SITS COED 
scale, the inter-observer agreement between experienced and more junior doctors was very 
good. Variants of similar scales to grade cerebral oedema, with 3 or 4 levels, have been used 
in several publications [105, 149, 101, 57, 150]. 
3.6 HAEMORRHAGIC TRANSFORMATION 
All papers use the same definitions of haemorrhagic transformation [145, 151, 141]. 
Haemorrhages were detected on CT or MRI. Every examination could be assigned one rating 
  33 
for local haemorrhage and one rating for remote haemorrhage. If there was no haemorrhage, 
this too was registered. 
Local haemorrhage  
• Haemorrhagic infarction (HI) type 1. Small petechiae along the margins of the 
infarction. 
• HI type 2. A more confluent petechiae within the infarction area but without space-
occupying effect. 
• Parenchymal haemorrhage (PH) type 1. Blood clot(s) not exceeding 30% of the 
infarction area with some mild space-occupying effect. 
• PH type 2. Blood clots exceeding 30% of the infarction area with significant space 
occupying effect 
Remote haemorrhage 
• Remote parenchymal haemorrhage (PHr) type 1. Small or medium sized blood clots 
located remote from the actual infarction; a mild space occupying effect could be 
present. 
• PHr type 2. Large confluent dense blood clots in an area remote from the actual 
infarction; significant space occupying effect may be present. 
In addition, paper I used 3 definitions of SICH [141]. SICH per SITS-MOST was defined as 
PH type 2 or PHr type 2 on the 22 to 36 hours post-treatment imaging, combined with a 
neurological deterioration of ≥4 NIHSS points on from baseline, or from the lowest NIHSS 
value between baseline and 24 hours, or leading to death. SICH per ECASS 2 was defined as 
any haemorrhage plus a neurological deterioration of ≥4 NIHSS points from baseline, or from 
the lowest NIHSS value within 7 days. SICH per NINDS was defined as a haemorrhage that 
leads to any neurological deterioration (NIHSS score ≥1) or death within 7 days. 
3.7 OTHER RADIOLOGICAL ASSESSMENTS 
In paper I, II and IV, infarction signs on CT or MRI were registered. The terminology used in 
the SITS Registry protocol is "current infarction", allowing the rating of yes, no or unknown.  
In paper I, II and IV, a thrombus was visualized as a HAS on CT images [152, 153], a visible 
occlusion on MRI images or an occlusion that was detected using CT angiography (CTA) or 
MRI angiography. Please see figure 15. In paper II, recanalization at 22-36 hours was 
inferred from disappearance of radiological signs of occlusion on computed tomography, 
MRI, or angiographic examinations. If records of more than one modality was available, 
angiographic data took precedence.  
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Figure 15. Computed tomography (CT) images from 
the iStroke Pilot Study. A. Hyperdense artery sign at 
the location of the right middle cerebral artery. B. CT 
angiography showing occlusion of the right MCA in 
the same patient. 
 
 
In paper IV, CT or MRI data was used to localize arterial occlusions within the cerebral 
vascular tree. Patients were classified according to side of occlusion (left, right or bilateral), 
whether the occlusion was in the anterior or posterior circulation and level of occlusion (for 
example, carotid T or MCA). The purpose of this was to identify patients with anterior 
circulation LAO. 
3.8 STATISTICAL CONSIDERATIONS 
3.8.1 Paper I  
The aim was to find the most important, or strongest, predictors. This involved calculating the 
odds ratio (OR) of outcomes that had to do with COED (for example severe COED), 
comparing patients with different values of predictors (for example HAS versus no HAS). 
The analysis was done using different definitions of the outcome. 
Using logistic regression, univariable relationships between baseline variables and each of 
these outcomes were investigated. To study the relationship over a range of values, 
continuous variables were categorized into quartiles. Logistic regression was used to address 
two questions: first, whether odds ratios differed across categories (test of homogeneity) and, 
  35 
second, whether there was a linear trend in the OR of the outcome with increasing values (test 
for trend).  
The procedure of selection of variables to keep in the models was done using a process of 
backward elimination starting with all statistically significant variables from the univariable 
analysis [154, 155]. After the procedure was done and models had been finalized, the 
predictive ability of final models was evaluated in two ways. First, performance regarding 
misclassification was calculated by the C-statistic, equivalent to the Area under the curve 
(AUC) for the Receiver operating characteristic curve [156, 154, 157]. Second, a Hosmer-
Lemeshow test, in which a non-significant result can rule out gross lack of fit of the model in 
question, was done [154].  
3.8.2 Paper II 
In an initial univariate analysis, baseline characteristics and outcomes between recanalized 
and non-recanalized patients were compared. In addition, baseline characteristics between 
patients with no or mild versus moderate to severe COED were compared. Analyses were 
done with mRS either dichotomized or in 7 steps with ordered logistic regression using the 
proportional odds model. Logistic regression methods compared crude and adjusted odds.  
As the goal was to use different methods to adjust for potential confounders, covariates were 
chosen using three strategies. The first strategy was to select all baseline variables associated 
(p<0.05) with moderate to severe COED. The second strategy was to perform stepwise 
backward elimination among baseline variables associated with either recanalization or 
moderate to severe COED. The third strategy was to select variables that potentially 
confound the association between recanalization and COED using a model of potential causal 
relationships that was created beforehand. This model was expressed as a directed acyclic 
graph [158-161]. Using the assumptions of this model, adjustment variables were first 
selected so that total the effect of recanalization on COED could be estimated. Since PH was 
hypothesized to act as an intermediate variable, the direct effect of recanalization on COED 
was estimated through adjustment for PH [162]. The predictive ability of all three models was 
evaluated by calculating AUC. The robustness of the results was evaluated with a sensitivity 
analysis using calculated E-values for the effect of recanalization on CED. E-values can be 
interpreted as the minimum strength of association (on the risk ratio scale) that an 
unmeasured confounder needs to have with both recanalization and CED, given covariates, to 
fully explain away the estimated effects [163, 164]. Finally, the effect of CED on the 
secondary outcomes was investigated, both crude associations and controlled for the baseline 
factors associated with moderate to severe CED.  
3.8.3 Paper III 
Treatment groups were compared with descriptive statistics for baseline, demographic and 
imaging data. Fishers exact test, two-sample t-test and median regression were used. he dose 
of imatinib was treated both as a categorical and a continuous variable. To analyse whether 
imatinib had any effect on the NIHSS score, different regression models were used, with and 
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without adjustment for EVT. Regression methods were used to look at separate time-points, 
to evaluate the mean effect over the entire time course and to compare the mean percentage 
NIHSS change from baseline. Logistic regression was used to analyse the association 
between treatment groups and functional independence. 
3.8.4 Paper IV 
Univariate and bivariate statistical analysis was performed using t-test without equal 
variances assumption, Pearson´s chi-square test and Kruskal-Wallis test. A significance level 
of p<0.05 was used throughout. To study influence of age on outcomes, we categorized age 
into decades, with lowest interval ≤30 years and highest interval ≥71 years, and into quartiles. 
To facilitate comparison with results from randomized trials, age was also dichotomized into 
≤60 years and ≥61 years. Estimation of proportions was based on reported cases, excluding 
unknown or uncertain values from the denominator. When modelling the association between 
baseline variables and outcomes using logistic regression, the baseline variables that were 
significantly associated in univariate analysis were included, adding sex and treatments (IVT, 
EVT, stroke unit care). Finally, the sensitivity of the results to missing data was evaluated. 
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4 RESULTS 
4.1 PAPER I 
After exclusion of patients with missing or uncertain data regarding COED, the study 
population consisted of 42 187 patients recorded at 752 centres in 41 countries. Median age 
was 70.  
4.1.1 Proportions of COED and haemorrhage at 22-36 hours 
The proportion of mild COED on follow-up imaging (22-36 hours or any extra investigation), 
was 12.5%. The incidence of moderate and/or severe COED was 10.2%, divided 
approximately 1:1 into moderate COED (4.9%) and severe COED (5.3%). Of all cases of 
mild, moderate or severe COED, >99% was detected on the 22-36 hours examination and not 
on any extra examination while only 3.5% had their COED status changed between the 22-36 
hours examination and any extra examination. 
Regarding haemorrhagic transformation, any local haemorrhage at 22-36 hours was seen in 
15.1% of all patients, please see table 3 (data not in paper I). In patients with moderate 
COED, any PH was observed in 17.5% (PH type 1 in 8.1%, PH type 2 in 9.4%). In patients 
with severe COED the proportions of PH were higher; any PH was observed in 33.0% (PH 
type 1 in 10.5% and PH type 2 in 22.5%). The proportion of all types of SICH increased by 
severity of COED. The most severe type of SICH, SICH per SITS-MOST, was detected in 
5.5% of patients with moderate COED and 15.9% of patients with severe COED, compared 
to 0.5% of patients with no COED.  
4.1.2 Predictors for COED 
Almost all baseline variables showed statistically significant differences between patients 
with no COED and patients with any COED. As the proportion of oral anticoagulant use was 
very low at 2.5%, this variable was omitted from analyses.  
Five baseline variables remained in all final multivariate models for all COED outcomes: 
baseline NIHSS score, HAS, higher blood glucose, impaired level of consciousness and signs 
of infarction at baseline. Please see table 4. The point estimates are of odds ratios from 
models of various COED outcomes that have to do with moderate or severe COED. The 
outcome in model A and B was that a patient had a certain level of COED instead of no 
COED while the outcome in model C and D was calculated using the whole study 
population. Results were similar across all models although the estimated odds ratios were 
higher in models A and B compared to models B and C. NIHSS score was the strongest 
predictor. Comparing patients with NIHSS score ≥17 versus 0-6 in model A, the OR for 
moderate COED was 15.4 (95% CI 11.5-20.6) while the OR for severe COED in model B 
was 16.5 (12.3-22.1). Patients with HAS at had an OR of 2.1 (1.9-2.4) for moderate COED in 
model A and 2.5 (2.2-2.8) for severe COED in model B. Blood glucose, impaired level of 
consciousness and signs of early infarction at baseline showed odds ratios between 1.2 and 
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1.9. Variables positively associated with only one or two outcomes were: diabetes mellitus, 
hypertension, atrial fibrillation, congestive heart failure and mean arterial pressure. Age and 
previous stroke were negatively associated with moderate COED. In addition to the five 
predictors already mentioned, the models for mild COED contained sex, onset-to-treatment 
time, hyperlipidaemia and atrial fibrillation. 
Calculation of receiver operating characteristics resulted in AUC 0.72-0.82, levels that are 
usually taken to be indicators a good discriminatory ability. The Hosmer-Lemeshow test 
indicated that gross lack of fit could probably be ruled out for all models except model B. 
 
 
Intracerebral haemorrhage N All 
COED 
No Mild Moderate Severe 
Local haemorrhage 42 178      
 No local haemorrhage, %  84.9 91.8 66.6 62.9 48.7 
 PH type 1, %  3.0 1.4 8.1 8.1 10.5 
 PH type 2, %  3.1 1.2 4.4 9.4 22.5 
 HI type 1, %  5.3 3.7 12.2 9.6 8.1 
 HI type 2, %  3.6 1.9 8.7 10.1 10.2 
Remote haemorrhage 42 177      
 No remote haemorrhage, %  96.9 98.1 94.3 92.2 89.4 
 PHr type 1, %  2.0 1.4 4.3 3.9 3.9 
 PHr type 2, %  1.1 0.5 1.4 3.9 6.8 
Table 3. Haemorrhagic transformation among patients in paper I, by cerebral oedema 
(COED) status, on follow-up neuroimaging at 22-36 hours or extra examinations. 
Abbreviations: parenchymal haemorrhage (PH), haemorrhagic infarction (HI), remote 
parenchymal haemorrhage (PHr). 
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Outcome 
OR of the outcome 
Additional  
predictor(s) 
Highest 
quartile  
of NIHSS 
score (≥17)  HAS 
Highest quartile  
of blood glucose 
(≥7.9 mmol/l)  
Impaired 
LOC 
Infarct 
signs 
A. Moderate 
COED 
(relative to no 
COED) 
 
15.4 2.1 1.2 1.4 1.3 Age*  
Previous 
stroke*  
Diabetes 
mellitus† 
Hypertension† 
Atrial 
fibrillation† 
Congestive 
heart failure† 
B. Severe COED 
(relative to no 
COED)  
 
16.5 2.5 1.9 1.6 1.5 – 
C. Moderate 
or severe 
COED  
(relative to no 
or mild COED)  
12.7 2.0 1.5 1.4 1.4 Atrial 
fibrillation† 
D. Severe COED 
(relative to no, 
mild or 
moderate 
COED) 
12.3 2.0 1.8 1.5 1.4 Mean arterial 
pressure† 
Table 4. Predictors that remained in the final multivariable models for moderate and/or 
severe cerebral oedema (COED) of paper I. Five predictors remained in all models: National 
Institutes of Health Stroke Scale (NIHSS) score, presence of hyperdense artery sign (HAS), 
blood glucose, impaired level of consciousness and infarction signs on CT. The various 
definitions of outcomes all had to do with COED. The table shows examples of odds ratio 
(OR) of the outcome. Abbreviations: hyperdense artery sign (HAS), level of consciousness 
(LOC) 
* Negative association (OR < 1.0) 
† Positive association (OR > 1.0) 
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4.1.3 Death and functional outcome at 3 months 
Follow-up with mRS at 3 months was completed for 33 737 patients (80% of study 
population). Increasing COED at 22-36 hours negatively affected outcomes at 3 months, 
please see figure 16. 
 
Figure 16. Distribution of modified Rankin scale (mRS) scores at 3 months among patients in 
paper I, by degree of COED at 22-36 hours: no (0) mild (1), moderate (2) and severe (3). 
Dashed line indicates mRS 0-2 and solid line indicates mRS 6 (death). The proportion of 
patients with good outcome (mRS 0-2) was 66% in those with no COED, 34% with mild 
COED, 12% with moderate COED and 5% with severe COED. The proportion of patients 
dead within 3 months was was 8% in those with no COED, 18% with mild COED, 39% with 
moderate COED and 65% with severe COED. 
 
4.2 PAPER II 
The study population consisted of 22 184 patients recorded at centres in 62 countries. Median 
age was 71 years and median NIHSS score at baseline was 16. Reperfusion therapy 
administered was IVT only (82.6%), IVT and EVT (13.8%) or EVT only (3.6%). 
Recanalization status was determined directly, using angiography, for 8.6% and indirectly, 
inferred from disappearance of hyperdense artery sign or disappearance of visible thrombus, 
for 91.4% of patients. Using this definition of recanalization, 64.1% of patients had 
recanalized at 22-36 hours. 
4.2.1 The effect of recanalization on early COED 
Overall, recanalization was associated with a 10.6% absolute risk reduction of moderate to 
severe COED at 22-36 hours (13.0% versus 23.6%, p<0.001), RR 0.55 (95% CI 0.52-0.58), 
crude OR 0.48 (95% CI 0.45-0.52). Please see figure 17. Ordered logistic regression showed 
a significant shift toward lower level of COED in recanalized patients; however, the 
proportionality assumption did not hold. Meanwhile, recanalization was associated with a 
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2.4% absolute increase of PH at the same examination (8.9% versus 6.5%, p<0.001), RR 1.37 
(95% CI 1.24-1.51), crude OR 1.40 (95% CI 1.26-1.56).  
 
 
Figure 17. Distribution of COED at 22-36 hours in patients without, and with, arterial 
recanalization at 22-36 hours (paper II). The line indicates that the absolute difference in 
proportion of moderate to severe COED was 10.6%. 
 
Table 5 shows a summary of models that estimated the adjusted effect of recanalization on 
moderate to severe COED. For selection of covariates for models, three different procedures, 
based on statistical testing or prior hypothesis, were used. In addition, all models were 
estimated with and without PH as a covariate. Adjusted OR for the effect of recanalization 
were similar to the crude OR, between 0.42 and 0.52. Adjustment for PH resulted in slightly 
lower point estimates for COED; however, the relative difference was at most 12%. Values 
for AUC ranged between 0.69 and 0.79; highest AUC values were seen in models adjusted 
for PH. E-values were similar (2.1-2.4) across all models. Two models with high predictive 
ability showed the following estimates: OR 0.52 (95% CI, 0.46-0.59), AUC 0.74, not 
adjusted for PH, and OR 0.46 (95% CI, 0.41-0.52), AUC 0.79, adjusted for PH. Restriction to 
the TACS subgroup (not shown in table) resulted in slightly lower point estimates. 
Regarding clinical outcomes recorded at 24 hours, recanalization was associated with a lower 
NIHSS (median 8 versus 16, p<0.001) and lower incidence of END (8.3% versus 14.5%, 
p<0.001). While the full NIHSS score was not used in a multivariate model, the lower risk of 
END after recanalization remained after controlling for baseline variables, adjusted OR 0.50 
(95% CI 0.45-0.55). 
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Procedure for selection 
of covariates 
Adjusted  
for covariates 
Adjusted  
for covariates and PH 
OR (95% CI) AUC  OR (95% CI) AUC  
1. Associated with 
moderate to severe 
COED* 
0.47 (0.43-0.51) 0.69 0.42 (0.38-0.45) 0.74 
2. Stepwise backward 
elimination†  
0.52 (0.46-0.59) 0.74 0.46 (0.41-0.52) 0.79 
3. A priori hypothesis‡  0.52 (0.48-0.56) 0.71 0.46 (0.42-0.50) 0.76 
Table 5. Regression models for the effect of recanalization on moderate to severe cerebral 
oedema (COED), in paper II. 
* All baseline variables associated (p<0.05) with moderate to severe COED in the study 
population: onset-to-treatment time, signs of acute infarction on imaging, blood glucose, 
mean arterial pressure, diabetes mellitus, hypertension, congestive heart failure, aspirin 
treatment, oral antihypertensive treatment, current smoker, atrial fibrillation, decreased 
consciousness, endovascular thrombectomy (EVT) and decompressive hemicraniectomy 
(DHC) 
† Stepwise backward elimination (p<0.05 to eliminate) among baseline variables associated 
(p<0.20) with either recanalization or moderate to severe COED. Number of remaining 
covariates: 10-13, varying between models. 
‡ Variables that potentially confound the association between recanalization and COED: 
age, onset-to-treatment time, National Institutes of Health Stroke Scale (NIHSS) score, stroke 
unit care. 
 
4.2.2 The effect of recanalization on death and functional outcome at 3 
months 
Follow-up of death and functional outcome at 3 months was recorded for approximately 80% 
of the study population. Recanalization was associated with a 13.6% absolute reduction of 
mortality (18.3% versus 31.9%, p<0.001), RR 0.58 (95% CI 0.55-0.61), crude OR 0.48 (95% 
CI 0.45-0.51). This effect remained unchanged after controlling for baseline variables, 
adjusted OR 0.48 (95% CI 0.45-0.53). Recanalization was associated with a 26.1% absolute 
increase of the proportion of patients scoring mRS 0 to 2 at 3 months (48.7% versus 22.6%, 
P<0.001), RR 2.16 (95% CI 2.06-2.26), crude OR 3.25 (95% CI 3.04-3.49). Please see figure 
18. This effect too remained largely unchanged after controlling for baseline variables, 
adjusted OR 3.20 (95% CI 2.96-3.46). Ordered logistic regression showed a significant shift 
in mRS toward better functional outcome in recanalized patients; however, the 
proportionality assumption did not hold.  
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Figure 18. Distribution of modified Rankin scale (mRS) scores at 3 months in patients 
without, and with, arterial recanalization at 22-36 hours (paper II). 
 
4.3 PAPER III 
Sixty patients were recruited. NIHSS score and age were well balanced between treatment 
groups. Median time from stroke onset to IVT was 86 (range 35-269) minutes. For patients 
receiving EVT, median time from onset to end of intervention was 290 (range 145-465) 
minutes with exact time missing for three patients. Patients receiving imatinib were given 
their first dose within 240 minutes (range 75-714) minutes.  
4.3.1 Intention-to-treat analysis (safety outcomes) 
After randomization, there were 15 patients in low-dose, 14 patients in medium and high-
dose and 17 patients in the control group. Four serious adverse events (2 in control and 2 in 
low-dose group) resulted in the death of 3 patients. Of the dead patients 2 were allocated to 
low-dose group but of these, 1 did not receive imatinib and 1 patient had received only 2 
doses. There was no likely connection between study treatment and serious adverse events, 
according to investigators and safety committee. There were 118 non-serious adverse events 
in 41 patients including 11 cerebral haemorrhagic events, in 9 patients, in the medium-dose 
group. There were 6 patients with itching and skin reaction and 4 patients with nausea and 
vomiting in the high dose group.  
4.3.2 Per protocol analysis 
There were 21 HI (6 in control) and 3 PH (1 in control), divided quite evenly among 
treatment groups. In addition, there were 4 PHr (0 in control). There was a total of 33 cases of 
COED, please see table 6, with moderate to severe COED being less frequent with higher 
doses. In fact, there were no cases of moderate to severe COED in the high-dose group. 
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Group N 
COED, n  
No Mild Moderate Severe 
Control 18 9 7 0 2 
Low dose (400 mg) 12 6 4 2 0 
Medium dose (600 mg) 13 5 7 1 0 
High dose (800 mg) 14 4 10 0 0 
Table 6. Cerebral oedema (COED) at day 1 or day 7 per treatment group of paper III. There 
were no cases of moderate or severe COED in the high-dose (800 mg) group. 
 
For the time points specified in advance by the protocol, the mean NIHSS score, adjusted for 
EVT, was significantly improved in the high-dose group compared to the control group: -5.28 
(95% CI -9.60 to -0.96) on day 1, -5.68 (95% CI -10.38 to -0.98) on day 7 and -4.81 (95% CI 
-10.39 to -0.98) at 3 months. 
Please see figure 19 for a graph of the mean NIHSS score per treatment group and time point 
between baseline and 90 days. On visual inspection, there seemed to be a tendency for higher 
dose groups to have lower NIHSS scores. Moreover, the mean unadjusted improvement in 
the NIHSS score compared to controls over all timepoints after baseline was 2 points for the 
low-dose group (p=0.283), 3 points for the medium-dose group (p=0.084) and 4 points for the 
high-dose group (p=0.037). After adjustment for EVT, the corresponding mean improvement 
compared to controls was 2 points (p=0.259), 3 points (p=0.106) and 5 points (p=0.012). 
Using linear regression, it was found that mean NIHSS score decreased by 0.50 points per 
100 mg imatinib (95% CI -0.98 to -0.02), and after adjustment for EVT 0.59 points  
(95% CI -1.08 to -0.09). 
Serum creatinine was modestly increased in the high-dose group versus the control group 
from baseline to day 7 (17% increases versus 0.5% increase, p-value for difference 0.010). 
Changes in other laboratory values, complete blood count, ALAT and ASAT, did not differ 
significantly between treatment and control groups. 
Functional independence (mRS 0-2) at 3 months was observed in 61% of the control group 
and 72% of all imatinib-treated patients. For the high-dose group there was a 18% absolute 
increase in the proportion of functional independence over the control group with OR, 
adjusted for EVT, 2.33 (95% CI 0.48-11.44), please see figure 20. 
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Figure 19. Mean NIHSS score per treatment group and time point in paper III. On visual 
inspection there seemed to be a tendency for higher dose groups to have lower NIHSS scores. 
The mean improvement in NIHSS score compared to control over all these time points also 
increased with higher dose. Statistical significance, however, was achieved only for the high-
dose (800 mg) group, in which an improvement of 5 points (p=0.012) was observed after 
adjustment for EVT status.  
 
 
 
Figure 20. Distribution of modified Rankin scale (mRS) scores at 3 months in patients of the 
control and high-dose (800 mg) groups of paper III. Line indicates functional independence 
(mRS 0-2). For the high-dose group there was an 18% absolute increase in the proportion of 
functional independence over the control group, adjusted OR 2.33 (95% CI 0.48-11.44). The 
numbers in this figure are slightly different due to rounding. 
 46 
In post-hoc subgroup analyses, among patients receiving high-dose imatinib, there were no 
local or remote haemorrhages in 2 different groups found by stratification: first, patients that 
received imatinib within 5 hours of stroke onset and, second, patients where reperfusion 
therapy (IVT alone or in combination with EVT) had ended within 4.5 hours of stroke onset. 
4.4 PAPER IV 
The study population consisted of 684 patients recorded at centres in 35 countries. Median 
age was 56 (range 20-86). Males were in majority (64.2%). Median NIHSS score at baseline 
was 18 (interquartile range 15-21). Any reperfusion therapy had been given to 98.1% of all 
patients; 52.5% received only IVT, 10.2% only EVT and 35.4% both IVT and EVT. Stroke 
unit care had been given to 73.5% 
Median and mean times between stroke onset and follow-up imaging were similar; median 
24.8 (interquartile range 18.8-27.3) and mean 23.3 hours. The prevalence of moderate to 
severe COED on follow-up imaging was 76.0%. However, no or mild COED was reported in 
some cases (15.9% and 8.1% respectively). Furthermore, 25.8% had PH. 
4.4.1 Death and functional outcome at 3 months 
486 patients (71% of the study population) had complete data on being alive or dead at 3 
months. The age distribution of this subgroup was similar to that of whole study population. 
A total of 159 patients (32.7%) died. Mortality increased with age as shown in figure 21. 
Among baseline variables, only increasing age was independently associated with death (OR 
1.06, 95% CI 1.03-1.08) in multivariate regression analysis.  
 
 
Figure 21. Mortality at 3 months increased with age in patients who underwent 
decompressive hemicraniectomy (DHC), as seen with age stratified by decades (n=486) from 
paper IV. 
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475 patients (69% of the study population) had complete data on functional outcome (mRS) 
at 3 months. Among these patients, good outcome (mRS 0-3) was observed in 66 (13.9%) 
and mRS 0-4 was observed in 187 (39.4%). Both outcomes decreased with increasing age as 
seen after stratification into quartiles and decades of age. Among baseline variables, 3 
variables were independently associated with good functional outcome in multivariate 
regression analysis, although with odds ratios close to 1: lower age (OR 0.95, 95% CI 0.92-
0.98) shorter onset-to-imaging time at baseline (OR 0.99, 95% CI 0.99-1.0) and lower mean 
arterial pressure (OR 0.97, 95% CI 0.94-0.99). 
4.4.2 Dichotomization of age at 60 years 
After dichotomization of age, the younger (≤60 year) subgroup had median age 51 and mean 
age 49.5 years while the older (≥61 year) subgroup had median age 67 and mean age 68.0 
years. Figure 22 shows functional outcome (mRS) at 3 months. There was a substantial 
difference in mortality between patients aged ≤60 years ≥61 years (25.2% versus 47.8%), 
absolute difference 22.6%. There was an 8.2% absolute difference in proportions of good 
outcome between patients aged ≤60 years ≥61 years (16.6% versus 8.4%). 
 
 
Figure 22. Functional outcome measured by modified Rankin scale (mRS) score at 3 months 
in patients who underwent decompressive hemicraniectomy (DHC), comparing age groups 
≤60 and ≥61 years (n=475) of paper IV. Lines indicates modified Rankin scale score (mRS) 
0-3 (good outcome) and mRS 6 (death). Not included here are the n=11 patients that were 
known to be alive at 3 months but hat no registered functional outcome. If they were 
included, the mortality was 25.2% (≤60 years) and 47.8% (≥61 years). 
 
4.4.3 Affected hemisphere 
Right-sided involvement of vascular territory was more common than left-sided. Among all 
268 patients with angiographic data, 60.4% had only right-sided and 38.4% had only left-
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sided occlusions, based on examination with CT (n=260) or MRI (n=8). After restriction to 
the 218 patients with carotid T or MCA territory occlusions, a similar pattern remained with 
62.4% right-sided versus 36.7% left-sided occlusions. Among 500 patients that were 
clinically evaluated for affected vascular territory, 55.0% were right-sided, 43.8% left-sided 
and 1.2% bilateral.  
4.4.4 Missing data 
198 patients (28.9% of the study population) did not contribute to calculations of mortality 
due to missing data. This subgroup had some baseline characteristics that indicate a better 
prognosis compared to the full study population, including less frequent imaging signs of 
acute infarction (27.0%), a higher proportion of IVT (89.9%) and EVT (48.0%) and a lower 
proportion of stroke unit care (67.7%). However, median age (57 years) was similar and 
median NIHSS was identical to the study population.  
Removal of the subgroup of 143 patients (20.9% of the study population) that had no data on 
assessment of vascular territory resulted in negligible changes to mortality and proportions of 
mRS 0-3 and mRS 0-4, indicating that they did not differ in a systematic way from the rest of 
the population.  
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5 DISCUSSION 
5.1 MEASUREMENT OF COED (ALL PAPERS) 
Early or mild COED is difficult to distinguish from infarction [78]. Increased signal on 
diffusion-weighted MRI under ischaemic conditions is caused by cytotoxic oedema [78, 79]. 
Since early ischaemic changes on CT are caused by ionic oedema, which is the earliest phase 
of transvascular oedema, some degree of local swelling, as seen on CT, is part of the 
ischaemic process [78, 79]. In contrast to mild COED, a rating of moderate or severe COED 
requires more radiological signs of swelling. In particular, moderate COED requires more 
signs of focal swelling while severe COED also requires midline shift. Therefore, the ratings 
moderate and severe COED probably have a progressively higher specificity to detect 
transvascular oedema.  
As there is no reference standard for COED, radiological or otherwise, there has not been any 
formal testing of the validity of the SITS COED scale or any other classification of COED. 
The definition of COED is imaging-based and not based on clinical findings or tissue 
analysis. The SITS COED scale measures COED in thirds of hemisphere and not according 
to vascular territories. It is however based on well-known facts about the natural course of 
COED. Furthermore, the work contained in this doctoral thesis has contributed to the 
documented use of this scale. 
Potential future uses for the SITS COED scale are for evaluation of treatments and for 
prediction scales. When implementing this scale, it should be considered that mild COED and 
cerebral infarctions are parts of very similar processes, so the utility of the scale may be 
greatest in moderate and severe COED. This should, however, be evaluated. 
5.2 PREDICTORS FOR COED (PAPER I) 
The findings that baseline NIHSS, HAS and signs of infarction at baseline imaging predicted 
COED development confirmed earlier results on COED in IVT treated patients [84]. Because 
HAS and signs of early ischaemia are associated with more proximal vessel occlusions and, 
thus, to larger infarction volume, our results are also consistent with previous findings that 
regardless of IVT treatment, a major predictor for cerebral oedema is the presence of a large 
ischaemic core at baseline, as measured by CT or MRI [106, 105, 93, 87, 150, 165]. 
Impairment of level of consciousness was found to be an independent predictor of all types of 
cerebral oedema and may be a consequence of early oedema, predisposing for malignant 
cerebral oedema, but may also have other causes such as hyperglycaemia or acute delirium 
with severe stroke as a predisposing factor [105, 166, 167, 20]. 
 
Baseline blood glucose was an independent predictor for COED development in our study. 
This adds confirmation of previous observations as similar associations have been suggested 
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but not statistically significantly associated in earlier studies [168, 84, 107]. An explanation 
for this may be an impaired BBB related to high levels of blood glucose [169-173]. 
Functional outcome at 3 months progressively worsened with increasing COED, in particular 
moderate and severe COED. This is consistent with previously reported data [84]. The 
absolute excess mortality at 3 months, compared with patients with no COED, was between 
10% and 57%. The 65% mortality at 3 months in severe COED was comparable to that of 
previous observational studies, as well as control groups of clinical trials of early 
decompressive hemicraniectomy [61, 116]. 
There have been some developments since this this paper was published. Ong et al. [174] 
published a score in 2017 to identify patients at high risk for lethal cerebral oedema in AIS; 
this score contained the following positive predictive factors: basal cistern effacement, high 
blood glucose, no tPA given or no EVT done, midline shift and no previous stroke. In a 
prediction score by Jo et al. [175], also published in 2017, 4 factors were independently 
associated with malignant cerebral oedema: higher baseline NIHSS score, early infarction on 
CT measured by the Alberta Stroke Program Early Computed Tomography Score 
(ASPECTS), worse collateral circulation and, lastly, failure of revascularization. Wu et al. in 
2018 [176] published a systematic review and meta-analysis where younger age, higher 
NIHSS score and larger parenchymal hypoattenuation on CT were reliable early predictors 
for malignant cerebral oedema and revascularization reduced the risk of malignant cerebral 
oedema. Miao et al. [177] in 2019 published a meta-analysis where a main finding was that 
the risk for malignant cerebral oedema is associated with severe clinical symptoms; they 
concluded that this is related to larger infarction volumes. It should be noted, however, that 
paper I of this doctoral thesis contributed a large majority of the patients in that meta-
analysis. 
5.3 RECANALIZATION AS A PREDICTOR FOR COED (PAPER II) 
As reported in paper II, recanalization was associated with an approximately 50% lower risk 
for early COED. The proportion of PH was higher in recanalized patients. Adjustment for PH 
resulted in slightly lower point estimates for moderate to severe COED. COED is also 
associated with SICH of different types. Nevertheless, the results remained consistent in three 
statistical models with different criteria for selection of covariates. 
This study strengthens the evidence for the hypothesis that recanalization decreases the risk 
of COED after AIS, in particular that early (within 22-36 hours) COED is decreased in 
recanalized patients. Previous studies on the association between recanalization and COED 
were not consistent [150]. Furthermore, in animal models, reperfusion has been shown to 
accentuate COED [178-181]. In contrast, recent clinical studies with different lengths of 
radiological follow-up indicate that recanalization decreases COED [182-184]. Together with 
our results, with differences about patient populations and definitions of cerebral oedema 
taken into account, this strengthens the evidence for a decreased risk of early COED after 
recanalization. There is also evidence that the risk of later COED is decreased [182, 185, 
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184]. A clinical scoring system for malignant cerebral oedema found that non-
revascularization at 24 hours was an independent predictor [175].  
On a tissue level, both cerebral oedema and haemorrhage seem to result from the same 
process of gradually increasing BBB permeability and damage [40]. Signs of increased 
permeability, detected as early BBB disruption on computed tomography scan, is seen in 
26.7% of patients after EVT [186]. Increased BBB permeability is associated with 
haemorrhagic transformation and cerebral oedema [187]. Our study showed that 
recanalization confers a lower risk of COED after ischaemic stroke and that this effect 
remains despite an increased rate of PH. It is consistent with the results of a multicentre 
retrospective study in which malignant MCA infarctions and mortality were reduced in 
patients undergoing EVT [188]. As the development of cerebral oedema in ischaemic stroke 
is multifactorial, persistent occlusion should be regarded as one important predictor together 
with other predictors that include the size of the ischaemic lesion which reflects on the 
NIHSS score, collateral status, and size of the occluded artery and the effect of thrombolytic 
drugs [53, 189, 99, 190, 41, 191].  
5.4 PILOT TRIAL OF IMATINIB IN ISCHAEMIC STROKE (PAPER III) 
In this phase 2, dose-finding trial, treatment with Imatinib with doses from 400 mg to 800 mg 
daily for 6 days in acute ischaemic stroke patients after IVT was safe and was well tolerated, 
at all doses. Although some patients experienced nausea or vomiting, or itching and skin 
reactions, when higher doses were used, tolerability was acceptable. 
It is worth noticing that the effect of imatinib on prespecified outcomes seemed to increase 
dose dependently, so that increases were largest in the high-dose group. Differences 
regarding the high-dose group, versus control, even reached statistical significance in some 
instances, also after adjustment for EVT status. The mean NIHSS score per treatment group 
and time point between baseline and 90 days improved with higher dose. This could be 
observed not only on visual inspection of the graph but also as increasing differences between 
dose groups and control with the difference between the high-dose group and control, 5 
points, reaching statistical significance. In a similar fashion, the mean NIHSS score at 
timepoints specified in advance, adjusted for EVT, was significantly improved in the high-
dose group compared to the control. For the high-dose group there was a 18% absolute 
increase in the proportion of functional independence over the control group. This 
observation needs confirmation in a phase 3 trial. 
There were no apparent differences between the treatment groups regarding proportions of 
haemorrhagic transformation. If imatinib restores the BBB, as is expected from experimental 
studies, some differences regarding haemorrhagic transformation between treatment groups 
could be expected. However, the sample size is small, and furthermore patients were divided 
into 3 dose groups. Also, the fact that imatinib was administered orally may have caused the 
effect to be too late. In post-hoc subgroup analyses, among patients receiving high-dose 
imatinib, there were no local or remote haemorrhages in patients that received the drug within 
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5 hours of stroke onset. Moreover, there were no moderate to severe CED in the high-dose 
group. Thus, there is some evidence indicating the conclusion that imatinib, when given early 
in a high dose, may decrease cerebral haemorrhage and oedema in ischemic stroke patients, 
consistent with the hypothesis that imatinib stabilizes the BBB. 
Cerebral ischaemia is a complex process with the extent of remaining brain injury and 
functional deficits being dependent on the interaction of several cell types in the cerebral 
vasculature and brain parenchyma. As reperfusion therapy in ischaemic stroke is becoming 
more effective, research is needed for drugs that treat and prevent the consequences of 
reperfusion injury [192, 193]. Meanwhile, the term neuroprotection has been used for many 
years but has sometimes been interpreted narrowly to include neurons and not any other cell 
types in the brain. As suggested by Diez-Tejedor et al. [194], "brain protection" would 
perhaps be a better word to use since the aim is to globally protect the whole organ. An 
alternative is "brain cytoprotection" [195]. A similar point was made in 2018 in a document 
prepared by working groups within the European Stroke Organisation outlining future 
research priorities for stroke. Norrving et al. [196] argued that the concept of neuroprotection 
has evolved and should become wider to include systems of neurons, glial cells, pericytes, 
macrophages and, not least, vasculature. Other key research mentioned included vascular 
protection and research into inflammatory responses. Several emerging pharmacological 
therapies may have potential effects of brain protection in a broad sense, for example through 
action on different parts of the neurovascular unit [197]. A drug being investigated as 
potential treatment against cerebral oedema is glibenclamid, also known as glyburide, a 
sulphonylurea that is routinely used to treat non-insulin dependent diabetes [198]. In a 
randomized phase 2 trial, glibenclamid was well tolerated in patients with anterior circulation 
AIS but unfortunately the trial had to stop early after 86 patients due to funding reasons 
[199]. A phase 3 trial (CHARM) is recruiting patients [200]. Several other potential 
treatments against cerebral oedema in other conditions than stroke are being evaluated in 
mostly phase 1 and 2 trials [201, 202]. 
An ongoing phase 3 placebo-controlled randomized trial, I-Stroke II, is now evaluating the 
effect of imatinib (800 mg/day) on functional outcome in ischaemic stroke. 
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5.5 INTEGRATION OF FINDINGS IN PAPER I, II AND III  
 
 
Figure 23. An interpretation of the results of paper I, II and III (denoted by roman numerals 
in black squares). Arrows with a minus ("–") sign denote a negative, or inhibiting, influence; 
all other arrows denote a positive influence. 
 
Please see figure 23 for an interpretation of results from paper I to III. According this 
somewhat speculative interpretation, 4 of the 5 important baseline predictors for COED 
presented in paper I (high NIHSS score, hyperdense artery, impaired level of consciousness 
and early signs of infarction) may be associated either with large artery occlusion (LAO) or 
extensive ischaemia of the anterior circulation in AIS. Furthermore, there is evidence from 
previous research that blood glucose, which was also a predictor for COED, is closely 
associated with, or even causative of, loss of BBB integrity. Reperfusion (paper II) decreases 
volume of infarction, thereby reducing damage to the tissue. Results from iStroke Pilot, a 
phase 2 safety study of imatinib (paper III) indicated that imatinib may reduce neurological 
disability in patients treated with IVT after AIS, which however remains unconfirmed while 
waiting for results from a further trial. Experimental evidence suggests that imatinib restores 
integrity of the BBB through molecular mechanisms, but this has not been shown in humans. 
Also depicted in the figure is the hypothesis that IVT has different effects; on one hand, the 
benefit of IVT using tPA in AIS is firmly evidence-based while on the other hand there is 
experimental evidence suggesting that tPA may contribute to damage to the BBB. 
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The results of damage to the BBB are twofold, as detected on neuroimaging at 22-36 hours. 
Transvascular (ionic and vasogenic) cerebral oedema is detected on the SITS COED scale. 
Haemorrhagic transformation is detected as local haemorrhage which may have a space-
occupying effect as in PH type 1 and 2. For example, among the patients of paper I, the 
proportion of local haemorrhage with space-occupying effect, that is either PH type 1 or PH 
type 2, was 17.5% in patients with moderate COED and 33.0% in patients with severe 
COED. Local haemorrhage may contribute to COED because of this space-occupying effect, 
as indicated by the dotted arrow. As observed in paper II, however, adjustment for PH 
resulted in only a small change of the effect of recanalization on COED, indicating that most 
of that effect was not mediated by local haemorrhage.  
5.6 DHC PATIENTS IN THE SITS REGISTRY (PAPER IV) 
In this large case series of ACS patients, of which the majority (98.1%) received reperfusion 
therapy and all underwent DHC, it was observed that as age increased, mortality increased 
while the probability of a good outcome at 3 months decreased. These were statistically 
independent associations. Similar associations have been observed in recent observational 
studies of DHC patients [203-205] while other observational studies seem to disagree [206, 
207]. In the present study, two thirds of all deaths occurred during the first 30 days after 
stroke onset. Moreover, there was a higher proportion of deaths at 3 months compared to 
RCTs at 6 months follow up (32.7% vs. 26%) [76]. Meanwhile, the proportion of good 
outcome (mRS 0-3) at 3 months was lower compared to RCTs at 6 months (13.9% vs. 20%) 
[76]. 
The differences in outcomes between this study population and randomized trials of early 
DHC could be attributed to a number of factors, only some of which were measured. The 
length of follow-up affects outcomes which could be seen as a shift between mRS categories 
between 6 and 12 months in randomized trials of DHC [115, 86, 121]. If the pattern in this 
study population was similar to those studies, there would after 6 or 12 months be more 
deaths, inflating the mortality, and a shift towards lower, i.e. better, mRS for the surviving 
patients. Later versus early DHC is associated with worse outcomes [208, 209]. However, 
timing of surgery was not registered. Diabetes has been associated with worse outcomes in 
DHC [208, 204]. Other predictive factors that have been described in DHC are infarction 
volume [210] and myocardial infarction [208], none of which were registered in this study. 
Similar to this study, a higher proportion of males compared to RCTs was observed also in 
other cohorts [203, 211]. This probably reflects the higher incidence of stroke among men 
compared to women [211]. 
The age distribution of this study population seems to be similar to randomized trials while 
outcomes still differ in subgroups of age. Patients aged ≤60 years had a mean age (49.5 years) 
that was comparable to the mean ages (43.2, 43.4 and 51.6 years) of the DHC treated groups 
in the 3 randomized trials that were pooled into an analysis with outcomes reported at 12 
months [116]. Compared to that analysis, these patients from the same age stratum had 
slightly higher mortality (25.2% at 3 months versus 22% at 12 months) and lower proportion 
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of good outcome (16.6% at 3 months versus 43% at 12 months). Patients aged ≥61 years had 
a median age (67 years) that was roughly similar to the median age (70 years) of the 
treatment group of DESTINY II which reported outcomes at 6 months [121]. Compared to 
DESTINY II, our patients from the same age stratum had higher mortality (47.8% at 3 
months versus 33% at 6 months) while the proportion of good outcome was similar (8.4% at 
3 months versus 7% at 6 months). However, the proportion of mRS 0-4 was lower (22.6% 
versus 39%). 
Involvement of right-sided vascular territory was more common than left-sided. Bias toward 
DHC patients having right-sided vascular involvement has been described earlier [212-214]. 
In addition, the finding that median NIHSS at baseline was around 4 points lower in right-
sided vascular involvement versus left-sided, was repeated [134, 133].The present results 
indicate that in this international cohort, there was a tendency to accept DHC in infarctions of 
the right (usually non-dominant) hemisphere versus the left (usually dominant) hemisphere, 
even though right-sided lesions had lower median NIHSS than left-sided. Reasons for this 
may include difficulty in neurological assessment or obtaining consent in aphasic patients as 
well as ethical considerations regarding the patient´s future quality of life. In a multicentre 
survey, physicians preferred DHC on the non-dominant side [215]. However, several studies 
have failed to show an influence on long-term functional outcome by affected side and such 
considerations are not recommended in guidelines [216-218, 111, 219]. 
5.7 METHODOLOGICAL CONSIDERATIONS AND LIMITATIONS 
5.7.1 Remarks on terminology 
Slightly different definitions of the widely used terms “predictor” and “outcome” can be 
found in the literature. The term predictor is related to exposure, determinant and, in 
multivariable models, independent variable [220, 131]. Terms related to outcome are 
endpoint, response and, in multivariable models, dependent variable [220, 131]. As the words 
are used in this doctoral thesis, a predictor temporally precedes and is associated with an 
increased probability of the outcome. A causal connection between predictor and outcome is 
not necessary; however, a research goal may be to infer a causal link. Examples of predictors 
include NIHSS score (paper I), recanalization (paper II), age (paper III) or imatinib treatment 
(paper IV). Some examples of outcomes are severe COED, mRS score 0-2 and being dead.  
5.7.2 Validity and precision 
Internal validity is the degree to which a study is free from systematic error and measures 
what it was intended to. Precision is the degree to which a study is free from random error 
[221].  
Sacket [222] described a classification of 35 types of different systematic error into 6 groups. 
A practical classification, however, is into 3 large groups: selection bias, information bias and 
confounding [223, 224]. Selection bias occurs when the sample is biased so that participants 
have a different association between exposure and outcome than the non-participants that 
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were left out of the study but were theoretically eligible [224]. It can be produced at any time 
during a study, for example as a result from the process of selecting study participants or as a 
result of loss-to-follow-up [225]. Information bias is measurement error which is also called 
misclassification. When misclassification of a variable is related to other variables, it can 
cause differential misclassification in which the association is over- or underestimated [224]. 
Cohort studies and randomized trials, for example, can be sensitive to differential 
misclassification where the outcome is misclassified depending on exposure [226]. 
Confounding occurs when a measured or unmeasured factor is associated with both exposure 
and outcome while not being a part of the causal pathway from exposure to outcome [227, 
228]. Confounding should be taken into account when assessing studies that aim for causal 
interpretations of associations. This is in contrast to studies that aim to predict an outcome or 
find an association that is not going to be causally interpreted, where confounding is usually 
less of a problem [154, 229]. 
Generalizability, or external validity, is a term for how well the results of a study can be 
applied to other populations that did not participate [221]. 
5.7.3 Limitations of registry studies (paper I, II and IV) 
Paper I, II and IV report observational studies based on retrospective analysis of data 
collected from the SITS Registry. These studies have some limitations that are shared by 
registry studies in general, as well as some limitations that are more or less specific for the 
SITS Registry.  
Limitations of registry studies in general 
Loss to follow-up is often an issue in observational studies [230]. If the mechanisms of loss 
are random, the precision of the study is diminished. If dropouts are differential by exposure, 
so that the patients selectively drop out from one of the exposure groups, there may be bias. If 
the losses are differential by both exposure and outcome, there is almost certainly selection 
bias [231]. This may however be difficult to ascertain. There was, however, evident loss to 
follow-up in all 3 studies. If for example patients with successful recanalization were 
selectively lost from follow-up at 3 months, there would be a potential for bias when 
evaluating outcomes at 3 months. 
There is potential for information bias in the assessment of outcomes [230]. Blinded 
evaluation is difficult to do. The exposure, which is known, may give rise to expectations 
from the medical professionals, from patients or from relatives when evaluating outcomes. 
This could affect clinical outcomes such as mRS or NIHSS and the result would be 
misclassification of outcome [226]. 
While the effect of random error decreases with the size of the study population, systematic 
error in principle does not change [226, 232]. So, as the study population grows, precision 
increases and confidence intervals become narrower, whereas systematic errors remain.  
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Confounding can occur because of measured or unmeasured factors. The researcher is in 
general bound by the data available [233]. This can make it difficult to statistically control for 
factors that are unmeasured, including medical therapy that may affect the outcome. 
Limitations specific for the SITS Registry 
While the organization of the SITS Registry facilitates data collection, it also contributes to 
the limitations of data from the SITS Registry, as has been previously noted [141, 234-236]. 
Data was reported by local investigators. Since there was no regular monitoring for source 
data verification after 2006, the researcher using the data cannot be fully certain that all data 
has been entered correctly and that all consecutive patients were included according to 
protocol. Consequently, the potential for systematic errors, such as selection bias or 
misclassification, has to be taken into account. However, in 2011-12, Karolinska Trial 
Alliance performed an independent monitoring of some selected Swedish centres and verified 
that data entered in the registry from these centres are accurate. Furthermore, the SITS 
Registry has a logical automatic validation system that prevents the entry of erroneous or 
impossible data in the registry, to some extent. Also, in 2002-2006, source data verification 
was done by monitors. 
There were probably differences in capacities and technical resources that, for example, 
affected the assessment of neuroimaging. 
Mortality data is for death of any cause, not cause specific for stroke. If a patient is missing 
from follow-up, the degree in activity in searching for the patient is up to the local 
investigator and probably varies between persons and hospitals.  
The patients of the SITS Registry are a selected group compared to the general stroke 
population, which may limit generalizability. In the data used in papers I, II and IV, patients 
had received reperfusion therapy. Patients receiving reperfusion therapy have more severe 
deficits as exemplified among patients in Sweden during 2018. Among all patients in the 
Swedish Stroke Register, the median NIHSS at baseline was 3.0. In patients that received 
IVT, median NIHSS score was 7.0, and in EVT treated patients the median was 15.0 [5]. 
Moreover, since patients in the SITS Registry were selected for reperfusion therapy, they may 
have less concomitant disease than patients with similar stroke severity that did not receive 
such therapy.  
5.7.4 Limitations and strengths of paper I  
17.5% (8450/42187) of the study population were lost to follow-up and did not contribute to 
data on death and functional outcome at 3 months. There may be selection bias. However, 
this was not further evaluated in the paper. 
Medical anti-oedema treatment was not recorded. However, no medical therapy for COED 
had been proven effective in controlled trials, and the rates of decompressive 
hemicraniectomy had been low in published studies.  
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The results describe COED at 22-36 hours or any extra investigation, the timing of which was 
not taken into account. However, extra investigations were very rare and only 3.5% of 
patients had their COED status changed between 22-36 hours and any extra investigation. 
An analysis of impact of infarction size on the development of COED could not be done 
since infarction size was not measured. 
The meaning of "important variable" was operationally defined by the statistical procedure in 
the paper so that the finally selected variables were those that remained in several models for 
different degrees of COED. Which variables get selected depends on implicit decisions of the 
researcher as well as aspects of design, for example which statistical method is chosen, cut-
off points of variables and choice of significance levels. This negatively affects the 
generalizability of results. That being said, however, the strengths of this paper were the large 
sample size of data collected at many hospitals from several countries and the adjusted 
analysis involving several variables that is accounted for in some detail in the paper. 
5.7.5 Limitations and strengths of paper II 
There was approximately 18% loss to follow up for the 3 months functional outcome, which 
may indicate a potential selection bias. 
For most of the study population, site of arterial occlusion could not be assessed through 
neuroimaging; it was inferred through a classification system with the aim of collecting 
patients with supratentorial large-vessel occlusion.  
There are some issues regarding the measurement of exposure. For most patients, the 
recanalization was indirectly detected through HAS as a surrogate marker for vessel 
occlusion. Moreover, time of recanalization was not observed. However, recanalization 
probably tended to occur early as all patients received recanalizing treatment. Recanalization 
followed by re-occlusion may theoretically have occurred, although unlikely. 
Since COED and PH were detected on the same neuroimaging examination, relations of 
temporality are not completely clear.  
There may be residual confounding. However, covariates were selected on both statistical and 
nonstatistical grounds and furthermore a test of robustness was used.  
The strengths of this study were the large sample size of data collected at many hospitals 
from several countries, the adjusted analysis and consistent results regardless of multivariable 
model. 
5.7.6 Limitations and strengths of paper III 
The study was planned as a safety study and the small sample size necessitates any 
observations on efficacy to be confirmed in a larger trial.  
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This was an open-label study. Patients and their relatives knew whether the patient was in the 
control group or received imatinib. If the patient was allocated to treatment, they may even 
have known to which dose group. With the exception of the final follow-up at 3 months, 
treatment groups were known all investigators and staff when they assessed clinical outcomes 
such as NIHSS scores. Thus, there was some potential for misclassification of clinical 
outcomes depending on treatment group, prior to the final follow-up, most likely based on 
people´s expectations of treatment in increasing doses improving outcomes more than 
control. However, regarding the direction of differences between treatment groups, the 
assessment of functional outcome and NIHSS score at 3 months were in agreement with 
results from the first 8 days. This is noteworthy since the evaluation at 3 months was done 
with the investigator blinded to treatment group. 
The frequency of EVT was substantially higher in the high-dose group than the other groups, 
including control. In the high-dose group 71% underwent EVT compared to 29% in the 
control group (intention-to-treat population). Since EVT improves the prognosis, there is 
potential baseline imbalance where patients undergoing EVT, thereby having a better 
prognosis, were included in the high-dose group. The randomization procedure should on 
average distribute pre-treatment factors, such as EVT, equally over treatment groups thus 
achieving comparability for the follow-up [237, 238]. However, randomization can be trusted 
to distribute factors evenly between treatment groups only on average and imbalances may 
remain, especially if the sample size is small [239, 224]. Furthermore, a successively 
increasing proportion of thrombectomies in the population from which study participants 
were sampled could hypothetically affect the high-dose group which was recruited towards 
the end of the study period, making it difficult to fully compensate for this imbalance with 
randomization. However, the results were adjusted for mechanical thrombectomy and, when 
stratified by thrombectomy, the result was fairly robust, although the number of patients was 
small. 
Most of the analysis regarding efficacy was done on the per protocol population instead of the 
intention-to-treat population, as is usually recommended in randomized trials, for example in 
the CONSORT statement [240]. Five patients were either moved between treatment groups 
or excluded. However, none of these 5 patients were taken from the high-dose group, and 
only 1 patient was moved to control group. Therefore, it is unlikely that this would cause an 
overestimation of the main finding of the per protocol analysis.  
The strengths of this study were the thorough registration of clinical and adverse events, 
thereby fulfilling the primary objective of this phase 2 trial, and furthermore the 
randomization procedure, the blinded reading of neuroimaging and the blinded follow-up at 3 
months. Finally, this was an example of a successful cooperation between 5 hospitals in the 
Stockholm region, including the study coordination that was needed in order to follow acute 
stroke patients during transfer between hospitals, in acute treatment and during follow-up.  
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5.7.7 Limitations and strengths of paper IV 
There were discrepancies in the data that could be explained by misclassification. For 
example, while most of the study population had moderate or severe COED at 24 hours, the 
presence of no COED in 15.9% and mild COED in 8.1% needs explanation. Later 
aggravation of COED is one plausible explanation. However, patients may instead have been 
included without having undergone DHC, since DHC status was entered once and there were 
no additional procedures to check that this information was correct. Another plausible 
explanation is misclassification of COED.  
There was loss to follow-up. Approximately 30% of DHC cases were lost to follow up in that 
they did not contribute to calculations of mortality due to missing data. This subgroup had 
some baseline characteristics that indicate a better prognosis compared to the full study 
population. It is likely that the results at 3 months, for the remaining patients, were biased 
toward higher mortality and worse functional outcome.  
The lack of data relating to the DHC procedure decreases the generalizability of the study. 
There are no data on timing, indications, complications or other surgery related details that 
affect the prognosis. The lack of timing particularly complicates comparisons with 
randomized trials, since late DHC is associated with worse outcomes. Another consequence 
of the lack of data is that we have to assume that, among patients in the study population, the 
indication for surgery was LHI. This is, however, a reasonable assumption given that all 
patients had ischaemic stroke and that we excluded a group of patients with data that was 
consistent with posterior circulation stroke. 
A strength of this study is the perspective on DHC applied in practice in 684 patients with 
data derived from an international database. In fact, this is one of the largest single 
observational study of DHC treated patients published. Furthermore, there is reason to 
believe that results regarding side of vascular lesions are robust and the over-representation of 
right-sided vascular lesions is distinct. 
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6 CONCLUSIONS 
The most important, or strongest, baseline predictors for early COED are baseline NIHSS, 
hyperdense artery sign, signs of early infarction, level of consciousness, and higher blood 
glucose, characteristics that from previous studies are known to be associated with either a 
large ischemic core at baseline or BBB damage. Based on these clinical predictors, patients at 
risk for space-occupying COED can potentially be selected for close monitoring or treatment. 
Before routinely doing this, however, our findings may need to be confirmed in a prospective 
study with a standardized reading of image data. At the least, results can be used to create 
hypotheses about links between risk factors for COED, which can generate ideas for new 
treatments.  
In patients with acute ischaemic stroke, recanalization was associated with a lower risk for 
COED, even after adjustment for higher rate for PH, in recanalized patients compared to non-
recanalized patients at 22 to 36 hours. These results strengthen recent study results.  
Treatment with imatinib, which in experimental studies of ischaemic stroke has been shown 
to improve blood-brain barrier integrity, is safe and tolerable in human subjects. Furthermore, 
results of this phase 2 safety study indicate that treatment with imatinib may reduce 
neurological disability in patients with acute ischaemic stroke who have received intravenous 
thrombolysis. Imatinib therapy is one of several emerging pharmacological therapies that 
may have potential effects of brain protection in a broad sense, for example through action on 
different parts of the neurovascular unit.  
In a case series of patients with anterior circulation AIS in which a majority (98.1%) had 
received reperfusion therapy, and all patients underwent DHC, there was a higher proportion 
of death and lower proportion of good functional outcome at 3 months follow-up compared to 
RCTs with longer and more complete follow-up. Furthermore, outcomes worsen with 
increasing age. Despite caveats due to the possibility of loss to follow-up and 
misclassification, the study results indicate that monitoring of DHC in clinical practice, for 
example in treatment registries, would be very beneficial for future patients. In fact, this 
should probably be done. Right-sided vascular involvement was more common than left-
sided which suggests that hemisphere (dominant versus non-dominant) in LHI may have an 
influence on treatment decision. This too requires further study and ethical discussions. 
In general, this doctoral thesis added new knowledge in several aspects of cerebral oedema in 
acute ischaemic stroke and a potential new pharmacological therapy for acute ischaemic 
stroke. As paper I, II and IV reported retrospective and observational studies, results of these 
studies should be read with caution and further studies are required to confirm these findings. 
Since paper III reported a safety study, efficacy results regarding imatinib are preliminary; a 
phase 3 randomized controlled trial of high-dose (800 mg/day) imatinib is ongoing in 
Sweden. 
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8 POPULÄRVETENSKAPLIG SAMMANFATTNING PÅ 
SVENSKA 
Stroke är den vanligaste orsaken till neurologisk funktionsnedsättning hos vuxna. Cirka 15% 
orsakas av blödning i hjärnan. Cirka 85% orsakas däremot av att en blodpropp täpper igen en 
eller flera artärer (pulsådror) i hjärnan vilket kan orsaka en infarkt, alltså en hjärnskada med 
neurologiska symtom, exempelvis förlamning eller afasi. Detta kallas ischemisk stroke. 
Orsaken till det uppkommer en blodpropp kan till exempel vara förmaksflimmer (en 
rubbning av hjärtats rytm) eller atheroscleros (åderförkalkning) i artärerna.  
Väggarna i hjärnans små blodkärl (kapillärer) består av celler som normalt är tätt 
sammanfogade och skapar en barriär (blod-hjärnbarriären). Om en infarkt uppstår så blir 
barriären mer genomsläpplig så att vätska, proteiner och eventuellt blod läcker ut till 
hjärnvävnaden. Ansamlingen av vätska och blod i hjärnvävnaden kallas hjärnödem. En 
patient som just drabbats av stroke kan på detta sätt försämras ytterligare med ökade 
neurologiska symtom och försämrad prognos. Denna påverkan brukar vara maximal cirka 3-5 
dygn efter strokeinsjuknande men kan märkas ännu tidigare, kanske efter bara några timmar. 
Vid stor hjärninfarkt kan utträdet av vätska, från artärerna till hjärnvävnaden, skapa ett så 
högt tryck inuti skallen att patienten dör. Risken för detta är störst vid infarkter som orsakas 
av att mellersta hjärnartären (kallas arteria cerebri media) täpps till eftersom infarkten då kan 
bli stor. Vid uppkomst av ödem så dör då cirka 7 av 10 patienter om ingen behandling ges. 
Syftet med detta projekt var att öka kunskapen om infarktrelaterat hjärnödem, faktorer som 
påverkar risken att utveckla hjärnödem och dess behandling.  
Faktorer som påverkar uppkomst av hjärnödem hos patienter med ischemisk stroke 
Vi gjorde en undersökning bland 42 000 patienter med syfte att hitta riskfaktorer för 
hjärnsvullnad hos patienter som just insjuknat i ischemisk stroke. Patienterna hade 
registrerade i ett internationellt register som kallas SITS (Safe Implementations of Treatments 
in Stroke) perioden 2002-2011. Målet var att hitta de faktorer som mest påverkade risken för 
hjärnödem. Alla dessa patienter hade behandlats med intravenös trombolys (propplösande 
läkemedelsbehandling). En röntgenundersökning, datortomografi (DT) eller 
magnetresonanstomografi (MRT), utfördes cirka 24 timmar efter insjuknandet. Hjärnödem 
definierades enligt en skala i fyra steg (inget, lätt, måttligt eller uttalat) enligt utseendet på 
röntgen.  
Vi fann att ungefär 10% av patienterna hade en måttlig eller uttalat ödem efter cirka 24 
timmar. Med statistiska analyser letade vi riskfaktorer för hjärnödem bland de data som fanns 
registrerade för patienterna. Den viktigaste riskfaktorn var stora neurologiska symtom vid 
ankomst till sjukhus, konstaterat genom höga poäng enligt skalan NIHSS (National Institutes 
of Health Stroke Scale) som är ett standardiserat sätt att mäta neurologiska bortfall och 
symtom. En patient med stora neurologiska symtom hade en flerfaldigt ökad risk för måttligt 
eller uttalat hjärnödem efter 24 timmar. Andra faktorer som var associerade med ökad risk för 
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hjärnödem vid 24 timmar var om röntgenundersökning visade tecken på blodpropp i en större 
artär i hjärnan, om patienten hade sänkt medvetandegrad, om det fanns en synlig infarkt på 
DT eller om blodsocker var förhöjt. Kunskapen kan potentiellt användas för att välja patienter 
för extra noggrann övervakning.  
Den största begräsningen i våra slutsatser är att eftersom vi inte själva kunde styra över 
datainsamlingen så kan det finnas andra faktorer som egentligen är viktigare eller bättre på att 
förutsäga hjärnödem.  
 Rekanalisering och risk för hjärnödem hos patienter med ischemisk stroke. 
Detta var en undersökning av risken för hjärnödem hos patienter där DT eller MRT visar 
tecken på att den artär som gav upphov till en patients strokeinsjuknande hade öppnats upp 
(rekanaliserats). Detta är viktigt då rekanalisering idag är grunden vid akut behandling av 
ischemisk stroke. Med intravenös trombolys (propplösande läkemedelsbehandling) och 
trombektomi (propplösning vid ett kateterburet ingrepp i hjärnans blodkärl) försöker man lösa 
upp blodproppen inom några timmar efter insjuknandet. En del tidigare forskningsresultat har 
pekat på en ökning av risken för hjärnödem vid rekanalisering. En sådan riskökning skulle i 
så fall kunna förklaras med att behandlingen återställer blodflödet i skadad hjärnvävnad där 
även blod-hjärnbarriären är skadad. Vi undersökte risken för hjärnödem hos de 22 184 
patienter i SITS-registret där den första röntgenundersökningen visade en tilltäppt artär i 
hjärnan. Alla patienterna fick någon behandling som syftade till rekanalisering. 
Röntgenundersökning 24 timmar efter insjuknandet gav information om dels rekanalisering 
och dels graden av hjärnödem. Hjärnödem definierades enligt en skala i fyra steg (inget, lätt, 
måttligt eller uttalat) enligt röntgen.  
Hos patienter där hjärnartären hade rekanaliserats var risken att drabbas av måttligt eller 
uttalat hjärnödem nästan halverad jämfört med patienter där artären fortsatte vara tilltäppt 
(13.0% jämfört med 23.6%). Denna fördel kvarstod trots att fynd av blödning i hjärnan vid 24 
timmar var lite vanligare hos de patienter där artären hade öppnats. Våra resultat talar alltså 
för att rekanalisering ger en påtaglig minskning av risken för hjärnödem.  
En begränsning i våra slutsatser är att vi för majoriteten av patienterna saknade säkra data på 
var någonstans i hjärnan blodproppen var belägen. Detta fick härledas indirekt, med hjälp av 
symtomen. En annan begränsning i våra slutsatser är att våra data om öppning av artärer har 
en viss osäkerhet då de mestadels kom från DT- och MRT undersökningar där blodproppen 
avbildades utan att man gjorde kontrastundersökning.  
Imatinib-behandling av patienter med ischemisk stroke 
Under 2011-2016 genomfördes på fem sjukhus i Stockholm iStroke-studien där läkemedlet 
imatinib gavs till 60 patienter i akutfasen av akut ischemisk stroke. Djurförsök med modeller 
av ischemisk stroke hade tidigare visat att imatinib kan öka blod-hjärnbarriärens täthet och 
minska negativa konsekvenser av ischemisk stroke såsom hjärnödem och blödning. Imatinib 
finns sedan tidigare registrerat för andra indikationer än stroke. Huvudsyftet var att 
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genomföra en fas 2-prövning av imatinib vilket innebar att man för första gången gav detta 
läkemedel till patienter som har stroke. Studien var randomiserad, det vill säga att slumpen 
avgjorde vilka patienter som fick behandling respektive inte fick behandling med imatinib. 
Imatinib gavs som tablett under 6 dagar med början samma dag som patienten togs in på 
sjukhus med akut stroke. Syftet var att studera biverkningspanorama samt anpassa en 
acceptabel dos.  
Det viktigaste resultatet av denna studie var att imatinib, givet till strokepatienter som har fått 
trombolysbehandling, har en god säkerhetsprofil med acceptabla biverkningar. Utöver det 
kan man inte dra några säkra slutsatser avseende effekten av imatinib vid ischemisk stroke. 
Man noterade emellertid en förbättring av de neurologiska symtomen framför allt hos de 
patienter som erhöll den högsta dosen imatinib (800 mg per dygn), vilket fordrar bekräftelse i 
en mer omfattande studie. Denna pilotstudie har nu följts upp av en större pågående studie av 
imatinib (iStroke del II).  
Kirurgisk behandling av patienter med hjärnödem efter ischemisk stroke. 
Vi redovisade 684 patienter ur SITS-registret som haft ischemisk stroke och sedan genomgått 
hemikraniektomi, en neurokirurgisk operation som brukar utföras vid stort hjärnödem. Vid 
operationen görs en hemikraniektomi vilket betyder att en del av skallbenet tas bort tillfälligt, 
så att hjärnan kan expandera utåt istället för inåt. Operationen är dekompressiv 
(tryckavlastande) eftersom den syftar till att minska trycket inuti skallen. Patienternas 
medianålder var 56 år, den yngsta patienten var 20 år och den äldsta var 86 år. De hade 
insjuknat med stora strokesymtom och nästan alla hade fått rekanaliserande behandling. Fler 
hade infarkt i höger hjärnhalva jämfört med vänster.  
Vid röntgenundersökning 24 timmar efter insjuknandet hade 75% ett måttligt eller uttalat 
hjärnödem enligt en skala i fyra steg (inget, lätt, måttligt eller uttalat). Patienterna följdes upp 
3 månader efter insjuknandet i stroke. Vid denna uppföljning registrerades att 13.9% hade ett 
utfall enligt modifierad Rankinskala mellan 0 och 3, det vill säga "måttlig 
funktionsnedsättning" eller bättre. Måttlig funktionsnedsättning innebär att patienten behöver 
viss hjälp, men klarar att gå utan hjälp av någon annan person. Andelen som hade dött någon 
gång mellan operationen och 3-månaderskontrollen var 32.7%.  
Dessa resultat, både funktionsnivå enligt Rankinskalan och andelen döda, är sämre än vad 
som redovisats i de noggrant utförda kliniska prövningar av dekompressiv hemikraniektomi 
som tidigare publicerats. Det skulle kunna tala för att detta ingrepp, när det utförs i 
rutinsjukvård, har ett sämre resultat än vad som tidigare redovisats i samband med 
forskningsstudier som utfört randomiserade prövningar.  
En begränsning i studien var att det inte fanns någon information registrerad om själva 
operationen eller hur lång tid som förflöt mellan strokeinsjuknande och operation. Resultatet 
bör alltså tolkas med försiktighet. Det är dock befogat att uppmärksamma denna patientgrupp 
och systematiskt följa upp de patienter som genomgår dekompressiv hemikraniektomi. 
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